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The influenza A virus is the causative agent of influenza virus disease – commonly 
known as ‘the flu’.  Considerable numbers of people are infected seasonally, with 
most illness resolving quickly.  The social and economic impact can be severe, and 
presents a significant burden for healthcare systems. 
Influenza A is a negative sense, single stranded RNA virus with a host-derived lipid 
envelope that can form both filamentous and spherical virions.  The genome 
encodes for at least 14 genes from eight RNA segments, the main focus of this 
report being on the ion channel matrix protein 2 (M2).  M2 is primarily responsible 
for allowing the flow of protons down the concentration gradient in early infection, 
when the virus is within an acidified endosome.  The lowering of the pH within the 
viral core triggers viral membrane fusion with the endosomal membrane, and 
facilitates release of the viral RNPs in to the cell cytoplasm. 
M2 is also known to interact with many of the other viral and cellular proteins 
during all stages of viral infection.  It binds to both the matrix protein 1, M1, and 
possibly interacts with the nucleoprotein, NP, as well as interacting with cellular 
factors such as Annexin A6, and cholesterol.  Biophysically, M2 is crucial during 
viral budding in that it provides the force necessary to induce negative gaussian 
membrane curvature which enables ‘pinching off’ of new virions. 
Here we show that the cytoplasmic tail (CT) of M2 is able to interact with many 
cellular proteins and processes, such as autophagy through LC3 binding, the cellular 
SUMO system through a SUMO interacting motif, SIM, and the cellular 
intermediate filament Vimentin.  We have used a myriad of techniques in an attempt 
to elucidate and characterise these interactions of the M2 CT, and how mutations 
in the M2 CT may ultimately affect viral morphology.  Further understanding of 
viral morphology being affected by other viral proteins and has been investigated 
through the study of live attenuated influenza viruses (LAIVs) used in seasonal 
vaccinations.  Through this, a medically applicable outcome of influenza 
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1.0 INFLUENZA VIRUS BACKGROUND 
Influenza A virus (IAV) is a pleomorphic virus of the Orthomyxoviridae family 
consisting of a segmented, single stranded, negative sense RNA genome 
(McGeoch, Fellner and Newton, 1976; Lamb and Choppin, 1983).  Responsible for 
seasonal outbreaks and occasional pandemics IAV is a major burden on health 
systems globally and is estimated to cost the US economy $87.1bn annually 
(Molinari et al., 2007).  Five to 15% of the Northern hemisphere’s population is 
estimated to be affected per annum (WHO) with 250,000–500,000 deaths globally 
per year (WHO, 2014).  The most severe illness occurs in immuno-compromised, 
elderly and very young individuals and is often followed by secondary bacterial 
pneumonia, resulting in significant morbidity and mortality. 
1.01 Influenza virus disease – ‘the Flu’ 
Infection with influenza A virus, the most clinically relevant of the three influenza 
virus types known to infect humans (Influenza B and C viruses being the others), 
causes disease in humans through infection of cells of the upper respiratory tract 
which leads to a myriad of symptoms.  These symptoms can present mildly 
(coughing, sneezing, ‘runny nose’ and headaches), and do in the majority of 
individuals infected with seasonal flu.  More serious symptoms such as high grade 
fever, severe muscle aches and pneumonia can occur in susceptible individuals, or 
during a highly infectious pandemic, and it is these instances of disease which cause 
concern for governments and healthcare systems across the globe.  Initial infection 
is through contact with an infected individual shedding virus, and transmission may 
occur through coughs and sneezes aerosolising droplets of fluid from the upper 
airways which can encapsulate and carry virus to a new host.  Good hygiene should 
be practiced in order to prevent viral introduction through the mouth, nose or eyes, 
by washing of hands before touching the face.  If the virus does enter the airway, 
viral attachment to host cells is facilitated by haemagglutinin on the viral surface 
binding to sialic acid residues on cell surfaces, whereby entry is facilitated.  
Infection with IAV eventually leads to cell death through continual membrane 
depletion by newly forming virions, as well as activation of cellular apoptosis by 




The potential for IAV to cause such an impact on society, both seasonally and 
through pandemic outbreaks, has necessitated comprehensive and vigilant drive for 
vaccinations, especially for ‘at risk’ groups such as the young, elderly and infirm.  
The two categories of IAV vaccines are live attenuated vaccines (LAIV) and 
‘killed’ vaccines, with the LAIV being administered via a nasal spray, and the killed 
through injection.  Both are produced through infection of embryonic chicken eggs, 
and subsequent preparation steps, be they isolation and purification of the LAIV, or 
formaldehyde inactivation of the killed vaccine viruses.   
1.1 INFLUENZA VIRUS COMPONENTS 
 
Figure 1 - (Structure of influenza virus, www.virology.ws/2009/04/30/structure-of-influenza-
virus/. Accessed 29.10.2018) 
The segmented, single strand, negative sense RNA genome of the IAV is split over 
eight RNA segments (McGeoch, Fellner and Newton, 1976; Lamb and Choppin, 
1983), where the genetic material codes for at least 14 proteins which can be 
broadly generalised in to belonging in two ‘families’ – structural and non-structural 
(Figure 1).  The non-structural proteins consist of the polymerase subunits – 
polymerase basic subunit 2 (PB2), polymerase basic subunit 1 (PB1), in some 
viruses polymerase basic subunit 1-F2 (PB1-F2) and the polymerase acidic protein 
(PA) encoded on segments one, two and three respectively, the RNA binding 
protein NP encoded on segment five, and the NS1 and nuclear export NEP (also 
known as NS2) proteins both produced from segment eight (Bouvier and Palese, 
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2008).  IAV’s has a remarkable ability to produce alternatively spliced and frame 
shifted copies of various proteins, each thought to have a specialised role.  One 
example is PA-X, which is the result of a plus one frameshift in segment three.  The 
resultant protein consists of 191 amino acids from the N terminal of PA, fused to 
61 frame shifted resultant amino acids, and is termed PA-X (Jagger et al., 2012).  
PA-X is implicated in modulating host cell gene expression, and is especially 
involved in attenuating disease response factors, such as the innate immune 
response, and thereby ism in fact, involved in attenuating the disease state in 
infected organisms (Gao et al., 2015; Hu et al., 2015).  By prolonging host survival, 
the ability and efficiency of a virus to propagate to other live hosts is increased.  
1.12 The viral polymerase (PB1, PB2, PA) 
The viral polymerase is a heterotrimeric complex of each protein produced from 
segments one, two and three (Taubenberger et al., 2005) and is a known determinant 
for host specificity (Subbarao, London and Murphy, 1993; Naffakh et al., 2000).  
The PB1 subunit is involved in sequential nucleotide addition during the RNA 
elongation stage of viral replication (Kobayashi et al., 1996), the PB2 component 
binds capped cellular mRNA (Guilligay et al., 2008) (and the IAV protein NP 
(Poole et al., 2004)) and the PA subunit contains the endonuclease active site 
responsible for cleavage (Dias et al., 2009; Yuan et al., 2009). 
1.13 NS1 and NS2 – the ‘non-structural’ proteins 
The NS1 protein has been implicated in the involved in nuclear export of unspliced 
M1 mRNA (Pereira et al., 2017) and many different host interactions 
(Tawaratsumida et al., 2014; Cheong et al., 2015; Kuo et al., 2016).  Its partner, 
NEP (NS2) was originally implicated mainly in the export of vRNP complexes 
(O’Neill, Talon and Palese, 1998; Neumann, Hughes and Kawaoka, 2000), but has 
since been shown to have, in addition, very diverse functionality, including being 
necessary for viral budding through cellular ATPase interaction (Gorai et al., 2012), 
and causing a push to favour vRNP production over host protein production (Robb 
et al., 2009; Mänz et al., 2012). 
The structural proteins are haemagglutinin (HA) encoded on segment four, 
neuraminidase (NA) on segment six, and the two matrix proteins M1 and M2, both 
produced from segment seven (Bouvier and Palese, 2008).  As well as the M1 and 
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M2 proteins on segment seven, certain strains of IAV have the ability through 
alternative splicing of this segment to produce two more, poorly characterised and 
understood ‘M’ proteins – M42 and M4 (Wise et al., 2012). 
1.14 Haemagglutinin and Neuraminidase  
HA is the most abundant viral surface protein, present in approximately a 10:1 ratio 
with NA (Mitnaul et al., 1996).  When inserted in to the membrane of a fully formed 
virus, is comprised of two subunits, HA1 and HA2 (Bosch et al., 1981) (N.B. further 
references to HA in this body of work will refer to the active complex of both HA1 
and HA2 in the viral membrane unless otherwise stated).  HA is formed as a 
precursor unit HA0, which undergoes homotrimerisation within the endoplasmic 
reticulum, before transfer to the site of budding via the Golgi apparatus (Gething et 
al., 1986; Copeland et al., 1988; Daniel N. Hebert, Brigitte Foellmer, 1995).  Once 
at the viral surface, HA is required for viral attachment to a host cell membrane by 
binding to terminal sialic acid residues at the end of carbohydrate chains (Weis et 
al., 1988), but is also essential for viral fusion mediated by the HA2 subunit once 
the virus is encapsulated in an acidic endosome (Durrer et al., 1996).  The acidic 
environment of the endosome causes HA to enter the ‘fusion state’, allowing the 
HA2 subunit to interact with the endosomal membrane (Garten and Klenk, 1999; 
Steinhauer, 1999) which plays a crucial role in the initial stages of infection, 
however this process is the target of some broad spectrum antiviral compounds 
already in clinical use in Russia and China, such as Umifenovir (Arbidol) (Kadam 
and Wilson, 2017).  The recognition of sialic acid acid residues by HA is a key 
determinant of IAV tropism (Kumlin et al., 2008), as different hosts display 
different, or differential, expression of N-acetyl or N-glycolyl linked neuraminic 
acids (Varki and Varki, 2007).  Human airway tissue displays primarily α-2,6 linked 
sialic acid residues in the upper airway, and α-2,3 in the lower airway, and therefore 
IAVs which cause disease and replicate efficiently in humans must preferentially 
bind these residues (Ito et al., 1997; Yamada et al., 2006; Auewarakul et al., 2007).  
As such, binding to α-2,6 residues facilitates more efficient IAV transmission, while 
a greater affinity to α-2,3 residues causes more severe disease.  IAV is classically 
an avian disease with its reservoir in the bird population (Webster, 1998), which 
displays primarily α-2,3 linked sialic acid residues, therefore the virus must adapt 
its HA binding specificity to display preference to α-2,6 sialic acid residues in order 
to take hold in the human population.  This receptor discrepancy is of vital 
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importance when it comes to the mixing of viruses in different host reservoirs.  Pigs 
are a reservoir for IAV (Brown, 2000) and pose a severe threat to emergent 
pandemic strains owing to the expression of both avian-type (α-2,3) and human-
type (α-2,6) linked sialic acid residues throughout their bodies (Nelli et al., 2010).  
When pigs are kept in poor conditions and open farms, mixing with birds, new IAV 
strains with the potential for human infection can arise through antigenic shift, as 
will be discussed later (Wenjun Ma, 2009), and this is especially problematic in 
south and south east Asia (Choi et al., 2005; Cyranoski, 2005). 
NA, like HA is a membrane anchored, extravirally facing glycoprotein (Gamblin 
and Skehel, 2010) of four identical subunits which comprise the enzymatic sites, 
attached to a stalk region (Varghese, Laver and Colman, 1983).  NA also recognises 
sialic acid residues as HA does (Varghese et al., 1992), with NA functioning to 
cleave these residues in late infection, to facilitate release of newly formed virions 
(Palese et al., 1974; Barman et al., 2004).  Owing to this sialic acid cleaving ability, 
NA is the target of small molecule pharmaceuticals used to treat influenza: 
Relenza® (zanamivir) and Tamiflu® (oseltamivir) (Gubareva, 2004).  These are 
structural analogues of sialic acid, and work to inhibit the enzymatic action of NA, 
thus retaining newly formed virus on the host cells.  Resistance to these inhibitors 
has been seen sporadically, but in general they remain clinically useful in both 
treatment and prophylaxis of IAV infection (Samson et al., 2013), in contrast to the 
M2 inhibitor amantadine and its derivatives, to which resistance has become 
widespread and are no longer recommended for use (Hurt, 2014).   
Aside from the enzymatic head domain of NA, the stalk is known to play a role in 
determining the efficiency of viral infection, through co-evolution with the changed 
seen in the active site, as it is needed to promote efficient folding of the NA head 
(Da Silva et al., 2013; Nordholm et al., 2013; da Silva et al., 2015).  Additionally, 
the NH2 terminal of NA is important in NA translocation and trafficking though the 
endoplasmic reticulum (Bos, Davis and Nayak, 1984). 
1.15 The matrix proteins 
Segment seven produces the matrix proteins, M1 and M2.  M1 is the most abundant 
viral protein (Calder et al., 2010), and forms the scaffold under the lipid bilayer of 
the virus to provide stability (Harris et al., 2001; Calder et al., 2010) and anchoring 
points for other viral proteins (Harris et al., 2006; B. J. Chen et al., 2008; Rossman 
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and Lamb, 2011).  M1 is able to multimerise upon this interaction with lipids, which 
is integral to the formation of new virions (Hilsch et al., 2014), and this occurs at 
the site of budding through these lipid interactions, and interactions with other viral 
proteins such as HA, NA and M2 (Rossman and Lamb, 2011).  M1 is also thought 
to play a key role in producing the force needed to drive the budding of new virions, 
both classically spherical (Gómez-Puertas et al., 2000) and filamentous (Elleman 
and Barclay, 2004).  In the mature virion, M1 provides the matrix necessary to allow 
the transmembrane HA and NA proteins to anchor (Lee, 2010) as well as binding 
to vRNPs (Boulo et al., 2007).  Binding to vRNPs is facilitated by a positively 
charged surface on M1 (Gagnon et al., 1997), and also prevents re-importation to 
the nucleus after NS2/NEP binding (Boulo et al., 2007).  M1 also de-polymerises 
at low pHs, that are achieved through the action of the M2 ion channel during 
encapsulation in an endosome during the initial stages of viral entry to a host cell, 
which allows release of the genetic material of the virus necessary for infection to 
progress. (Batishchev et al., 2016; Shtykova et al., 2017).  Furthermore, M2 is able 
to induce negative membrane curvature at the site of budding, to facilitate the 
release of newly formed virions (Schmidt, Mishra, Wang, DeGrado, et al., 2013). 
1.2 ANTIGENIC VARIATIONS – DRIFT AND SHIFT 
IAV poses such a global health threat owing to its ability to emerge as antigenically 
novel viruses season to season, through display of genotypically novel HA and NA 
surface proteins (Gerhard and Webster, 1978; Both et al., 1983; Schweiger, Zadow 
and Heckler, 2002).  This phenomenon is known as antigenic drift, and an emergent 
antigenically novel HA, NA or double mutant appears in the global IAV circulation 
every two to eight years (Joshua B. Plotkin, Jonathan Dushoff, 2002; Smith et al., 
2004; Koelle et al., 2006).  The new and antigenically distinct ectodomains of HA 
and NA arise from point mutations in the viral genome (Sandbulte et al., 2011) and 
become a health concern as previously immunised individuals’ immune system will 
be naïve to this new strain of IAV.  Antigenic drift in IAV is the cause of a rise and 
fall in severity of flu seasons, and this is especially significant when there is a 
mismatch between the global stock of immunisations having been produced 
through modelling and prediction (Grohskopf et al., 2016, 2017; Grohskopf, 
Sokolow and Broder, 2018) versus what may be circulating.  So, antigenic drift 
poses a seasonal threat not only as immune-competent individuals can select for 
point mutant viruses and become infected themselves, but as there is limited cross-
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protection between antigenically drifted IAV, this can further add to the burden on 
public health (Epstein, 2018). 
As well as antigenic drift, IAV can undergo a wider, more complex and dangerous 
genotypic reassortment known as antigenic shift.  Antigenic shift occurs when two 
IAV strains mix in one host, and there is interchange between the vRNP segments.  
For example, one virus can exchange the entire segment four (HA) and / or segment 
six (NA) (Webster et al., 1982).  Antigenic drift is a process which produces 
antigenically-novel mutants slowly, enabling response from public health 
authorities.  Comparably, antigenic shift produces a completely novel and distinct 
virus which poses an immediate threat (Cox and Subbarao, 2000) which may 
overwhelm a population on a local, national or frequently global level – a pandemic.  
These new ‘H’ and ‘N’ mutant viruses give rise to the well-known nomenclature, 
such as H1N1 and H5N1, colloquially named swine flu and bird flu respectively 
due to their original hosts.  Current circulating seasonal strains are all descendants 
of past pandemics (Subbarao et al., 1998),  with the deadliest being the 1918 
‘Spanish flu’ (Figure 2).  This variant emerged as the result of a circulating avian 
influenza becoming pathogenic in the human population (Pennington, 2008) and 
caused the deaths of up to 50 million people, with even this figure the subject of 
some dispute (Johnson and Mueller, 2002).   
Figure 2 - Image taken from Belshe, 2005 “The Origins of Pandemic Influenza — Lessons from the 





Figure 3 (taken from Kim, Webster and Webby, 2018) shows the wide array of 
organisms capable of acting as reservoirs for IAV strains, and the possibility of shift 
occurring in organisms, allowing for a virus with increased pathogenicity.  Put 
simply, antigenic shift in IAV requires infection in an applicable animal reservoir 
of two different subtypes.  In a single concurrently infected cell, whole gene 
segments can be translocated between viruses during the infection and replication 














Figure 3 – Host species for IAV taken from Kim, H., Webster, R. G. and Webby, R. J. (2018) 
‘Influenza Virus: Dealing with a Drifting and Shifting Pathogen’. 
IAV infects the cells of the upper respiratory tract, causing illness in a wide range 
of hosts, including humans, pigs, horses and birds.  Birds are thought to be the 
reservoir for IAV in the wild (Parrish, Murcia and Holmes, 2015) and are a key 
source for the emergence of novel IAV strains (Sharp et al., 1997), such as the 1918 
Spanish flu.  Recent strains emerging from the wild bird population include the high 
21 
 
pathogenicity avian influenza virus strains H5N1 and H7N9, currently circulating 
in Eastern Asia where they have up to a 60% case-fatality rate in humans, though 
do not yet spread efficiently from person to person (Cowling et al., 2013). 
1.3 THE VIRAL LIFECYCLE 
The IAV life cycle can be broadly categorised in to three sections: entry, replication, 
and budding (Figure 4).  During the entry phase, viral HA attaches to sialic acid 
residues on the host cell surface, triggering endocytosis and the encapsulation of 
the virus in an acidic endosome.  The low pH both triggers HA-mediated fusion of 
the virus and endosomal membranes and enables protons to enter the viral core, 
mediated by the ion channel M2.  The acidificication of the viral core enables vRNP 
dissociation and following fusion of the viral membrane with the endosomal 
membrane vRNPs are released in to the cytoplasm where a nuclear localisation 
signal enables entry of the vRNPs in to the host cell nucleus where mRNA synthesis 
takes place.  Nascent viral proteins are produced from mRNA and some trafficked 
and modified through the Golgi apparatus.  vRNA is used to form progeny vRNPs 
which are exported from the nucleus by M1 and NS2.  Assembly occurs at the 
plasma membrane of the host cell, where M1 polymerisation primarily provides the 
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force to drive virions to bud, M2 induces negative membrane curvature to close the 
base of the budding virus off form the host cell plasma membrane, and NA cleaves 
reattached sialic acid residues, freeing the budded virus. 
Figure 4 – The viral lifecycle.  Image taken from von Itzstein, 2007 “The war against influenza: 
Discovery and development of sialidase inhibitors” showing a simplified schematic of the stages of 
the IAV lifecycle. 
1.31 Viral assembly and budding 
It is thought that IAV assembly and budding occurs at lipid raft domains on the 
apical surface of the host cell plasma membrane, where IAV proteins are brought 
together in high concentrations within specific membrane regions (Scheiffele et al., 
1999).  NA and HA are both fundamentally associated with these domains, with the 
transmembrane domain of HA promoting the raft association (Zhang, Pekosz and 
Lamb, 2000).  HA has the ability to induce budding of virus-like particles (VLPs) 
in and of itself, forming vesicles similar in appearance to viruses (Chen et al., 2007).  
This suggests that HA may possess an intrinsic capacity to alter membrane 
curvature.  Alternatively, the induction of membrane curvature may be driven by 
the crowding of HA molecules within a defined space (i.e. within a lipid raft 
domain).  However, HA VLP budding only produces spherical particles, whereas 
VLPs are filamentous when M1 is also expressed (Chlanda, Schraidt, Kummer, 
Riches, Oberwinkler, Prinz, Kräusslich and John A G Briggs, 2015).  After the 
formation of a viral bud, the virus remains attached to the host cell through a small 
membrane neck.  At this point, the M2 protein alters membrane curvature, 
constricting the neck and causing membrane scission (Schmidt, Mishra, Wang, 
Degrado, et al., 2013).  The enzymatic action of NA can then release the fully 
formed virus from the host cell.  Throughout this process, it is not clear when the 
genome is recruited to the budding virion nor the effects RNP binding has on the 




1.4 VIRAL MORPHOLOGY 
IAV is a pleomorphic virus, known to display a range of morphological states, from 
filamentous to spherical, with ovoid or bacilliform intermediates often observed 
(Figure 4b).   
Figure 4b - TEM images of a spherically budded A/Udorn/72 virion from infected MDCK cell (left) 
and a viral filament from A/California/0709 (right). 
In certain cases, IAV strains may produce solely spherical virions; however, 
filament-producing strains always produce a mixture of both filamentous and 
spherical virions.  It is known that filamentous viruses contain only one copy of the 
IAV genome, thus each sphere, bacilliform or filament is thought to be a single 
infectious unit regardless of length (Roberts, Lamb and Compans, 1998).  
Structurally, viral filaments are roughly equal, or slightly smaller in diameter (80–
100 nm) to spherical virus (120 nm), but extend to a significant length, sometimes 
upwards of 20 μm, with lengths over 50 μm not unheard of.  Filamentous viruses 
are particularly of note as they are recurrently observed in human clinical infections 
(Chu, Dawson and Elford, 1949; Choppin, Murphy and Tamm, 1960; Kilbourne 
and Murphy, 1960; Lang et al., 1968; Hayase, Y., Uno, F. & Nii, 1995; Shortridge 
et al., 1998; Itoh et al., 2009; Elton et al., 2013; Seladi-Schulman, Steel and Lowen, 
2013), for example, filamentous virions are seen in lung sections from fatal cases 
of the 2009 H1N1 pandemic (Basu et al., 2011).  In contrast, many laboratory 
strains produce solely spherical virions.  The biological function of this morphology 
is not known nor is it understood how host adaptation can select for a specific viral 
morphology; however, repeated passaging of filamentous human clinical isolates in 
chicken eggs causes a morphological adaptation resulting in the production of only 
spherical virus (Kilbourne, 1959; Choppin, Murphy and Tamm, 1960) whereas 
adaptation to growth in guinea pigs restores filament formation (Seladi-Schulman, 
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Steel and Lowen, 2013).  Mutations of several different viral proteins can influence 
filament formation during the process of adaptation.  For example, the filamentous 
A/Udorn/72 strain becomes spherical with a single point mutation in the M1 protein 
(Zebedee and Lamb, 1988, 1989; Roberts, Lamb and Compans, 1998).  Thus, a 
range of both host and viral factors governs the formation of filamentous virions 
during influenza virus assembly and budding. 
1.41 Viral determinants of morphology 
Many different studies have investigated the viral factors that determine 
morphology, with most focusing on the structural proteins M1 and M2 and their 
role in viral assembly. M1 plays a crucial role in the assembly and budding of both 
filamentous and spherical IAV (Scheiffele et al., 1999; Zhang, Pekosz and Lamb, 
2000). In 2004, Elleman and Barclay reported that M1 was also the main viral 
determinant of filamentous morphology (Elleman and Barclay, 2004). Swapping 
the ‘M’ RNA segment from the spherical strain, A/Puerto Rico/8/1934 (PR8), with 
the M segment of the filamentous strain, A/Udorn/1972 (Udorn), enabled the 
conversion of a spherical strain into a filamentous strain (when M-Udorn was 
inserted into PR8) and a filamentous strain into a spherical strain (M-PR8 into 
Udorn) (Zebedee and Lamb, 1989; Scheiffele et al., 1999). In 2007, Chen et al. 
showed that M1 is required for the formation of filamentous VLPs, though it was 
not required to form bacilliform (<1 μm) or spherical VLPs (Gómez-Puertas et al., 
2000; Bourmakina and García-Sastre, 2003; Chen et al., 2007). 
Interestingly, in filamentous viruses, M1 appears to adopt a helical conformation 
(Edinger, Pohl and Stertz, 2014), which is not apparent in spherical virus, 
suggesting that structural variations in the M1 protein may govern viral structure 
(Fujiyoshi et al., 1994).  This has been further investigated when Burleigh et al. 
demonstrated that a number of mutations in M1 can significantly influence the 
morphology of budding virus, from spherical to filamentous, with aberrant ‘in-
between’ morphologies (Burleigh et al., 2005).   
As the most abundant viral protein, M1 forms a layer under the viral envelope and 
is responsible for interacting with NA, HA and M2 to form a scaffold-like complex 
(Nayak, Hui and Barman, 2004). It is postulated that M2 can stabilise this complex 
during budding to allow for continued M1 polymerisation and the formation of a 
viral filament (Rossman et al., 2010). In support of this hypothesis, it has been 
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observed that mutation of the M2 protein can dramatically affect viral morphology, 
with mutations in the c-terminal amphipathic helix converting a filamentous virus 
into a spherical one (Rossman et al., 2010), whereas truncation of the c-terminus at 
residue 70 enables filament formation from an otherwise spherical virus (McCown 
and Pekosz, 2006). The effect of M2 on viral filament formation has also been 
studied using the monoclonal antibody 14C2, which has been shown to inhibit 
filamentous virus formation whilst permitting spherical virus to bud (Rossman et 
al., 2010). 14C2 binds to the ectodomain of M2 and is thought to disrupt the binding 
between the M2 cytoplasmic tail and M1 (Rossman et al., 2010). This is consistent 
with other data showing that mutation of the M2 cytoplasmic tail between residues 
70–77 reduces M1-M2 interactions and subsequently the amount of M1 and RNP 
packaged in virions (Grantham et al., 2010; Beale, Wise, Stuart, Benjamin J. 
Ravenhill, et al., 2014). Intriguingly, a single amino acid substitution in the M2 
cytoplasmic tail of the filamentous Udorn strain, Y76A, significantly reduced the 
number and length of filamentous viruses produced (Grantham et al., 2010). 
However, recovery of the filamentous morphology was seen with the addition of a 
S71Y mutation, though it is not clear if these mutations also affect M1-M2 
interactions (Grantham et al., 2010). In either case, it is possible that the M2 protein 
affects viral filament formation by altering membrane curvature, stabilising the site 
of budding and therefore enabling M1 polymerisation and the elongation of a viral 
filament (Wharton et al., 1994; Gubareva, 2004). Thus, M2 appears to modify 
filament formation through binding and recruitment of M1, whereas M1 itself is 
required for the actual structuring of the filament. This suggests that filamentous 
virion production is likely a multi-faceted process, affected by several different 
viral proteins, all occurring in the context of an array of cellular partners. 
1.42 Host determinants of morphology 
IAV is pleomorphic, adopting both spherical and filamentous forms (Fujiyoshi et 
al., 1994). As described, viral morphology can be altered through adaptation to 
different hosts, implying that there are host-specific influences on filament 
formation (Seladi-Schulman, Steel and Lowen, 2013). Filamentous IAV is 
consistently found in human clinical isolates from laboratory confirmed cases, in 
the 2009 H1N1 pandemic (Basu et al., 2011) and as far back as the 1957–1958 
pandemic (Kilbourne, 1959), with the first identification having occurred in 1946 
(Mosley and Wyckoff, 1946). It is known that filament forming strains become 
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spherical after repeated passage in embryonated chicken eggs, whereas the 
filamentous morphology is retained during passage in Madin-Darby canine kidney 
(MDCK) cells (Burnet and Lind, 1957; Choppin, Murphy and Tamm, 1960; Seladi-
Schulman, Steel and Lowen, 2013). Thus, host cell factors play a considerable role 
in filament formation, and IAV morphology may represent an adaptation to a 
specific host cell environment. Previous research has identified several host 
proteins that affect viral morphology. In particular, when the Udorn virus is grown 
in polarised MDCK cells, filamentous virus is produced from the apical plasma 
membrane (Fujiyoshi et al., 1994; Scheiffele et al., 1999; Zhang, Pekosz and Lamb, 
2000). Chemical disruption of the actin cytoskeleton causes depolarization of the 
cells and specifically reduces filamentous virus production whilst having no effect 
on the budding of spherical virus (Roberts and Compans, 1998). Considering that 
the upper respiratory tract consists of highly polarised epithelial cells and is the 
primary site of human infection, the detection of filamentous IAV in human clinical 
samples may be directly related to epithelial cell polarisation. However, other 
experiments have shown that human embryonic kidney 293T cells are capable of 
producing filamentous virions, despite an absence of cell polarisation and a lack of 
a defined apical membrane (Bruce et al., 2009). Thus, the impact of cell polarisation 
on viral morphology may be more complicated and may be influenced by other host 
cell proteins or processes. 
1.43 Significance of viral morphology 
The biological significance of IAV morphology in human clinical infections is a 
subject of great interest.  The production of viral filaments appears to be highly 
inefficient by its nature, consuming anywhere from three to thirty times the amount 
of plasma membrane used to bud one infectious virus (Mosley and Wyckoff, 1946; 
Roberts and Compans, 1998).  There are several opinions on why, despite this 
apparent inefficiency, IAV readily produces filamentous virus in human clinical 
infections.  As there is always a mixed population of spheres and filaments and 
never solely filaments, it is possible that the two morphologies are playing different 
roles within the host.  It has been found that filament forming mutants of PR8 have 
higher per-molecule NA activity in vitro (Seladi-Schulman et al., 2014).  In 
addition, NA has been shown to cleave sialic acid bonds within the mucus secreted 
by airway epithelial cells (Cohen et al., 2013; Yang et al., 2014) and the greater 
number of NA molecules (owing to a longer viral length) may serve to more 
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efficiently clear this mucus layer.  It is therefore plausible to think that the 
filamentous morphology is actually a marker of pathogenicity in vivo, whereby 
mucus in the airway is cleared by NA on filaments, thus allowing for a more 
efficient spread of the smaller spherical viruses (Vijayakrishnan et al., 2013).  This 
hypothesis is supported by a recent study that suggests that filaments are not 
released as efficiently as spheres from cells and may remain as cell-associated 
virions (Gómez-Puertas et al., 2000). 
In 1998, it was shown that spherical and filamentous viruses are comparably 
infectious in vitro and both contain a single copy of the viral genome (Roberts and 
Compans, 1998; Noda et al., 2006; Calder et al., 2010; Vijayakrishnan et al., 2013).  
However, it has recently been reported that certain subsets of filamentous virions 
may lack a genome (Vijayakrishnan et al., 2013).  Vijayakrishnan et al. (2013) 
reported that longer filaments were typically devoid of a copy of the viral genome, 
whereas shorter filaments were not.  Thus, there might not be a single type of 
filamentous virions, but rather a range, potentially with different functions.  In the 
tightly packed epithelial layer of the upper respiratory tract, short, cell-anchored, 
infectious filaments may be able to directly deliver the viral genome to 
neighbouring cells without the need to release and transmit a viral particle.  This 
process may be facilitated by the more permissive use of macropinocytosis as an 
alternate cell entry pathway, used by filamentous IAV (Sieczkarski and Whittaker, 
2005; de Vries et al., 2011; Rossman, Leser and Lamb, 2012).  At the same time, 
longer, non-infectious filamentous virions may serve to thin and clear host 
respiratory mucus, facilitating the spread of spherical virions to neighbouring cells 









1.5 THE MATRIX PROTEIN 2, M2 
Within the last decade, much focus has been on the wide and varying roles of the 
M2 protein.  M2 is a proton channel, with this well characterised ability playing a 
crucial role in initial viral infection (Pinto, Holsinger and Lamb, 1992).  Once 
endocytosed, the low pH of the endosome which encapsulates the virion is exploited 
by M2.  Protons are allowed to flow down the concentration gradient by means of 
M2, entering the viral core (Figure 5).  The decreased pH within the virus causes 
dissociation of vRNPs from M1, and subsequent release in to the cytoplasm of the 
























Figure 5 – The M2 ion channel.  Image taken from Schmidt et al., 2013 Influenza Virus A M2 Protein 





M2 is a relatively small, 97 amino acid, ~14 kDa protein which exists as part of the 
virus in a homotetramer.   M2 is a transmembrane protein with an externally facing, 
antigenic ectodomain, a transmembrane domain containing the ion channel pore, 
and an internal cytoplasmic tail, responsible for many viral-viral and viral-cellular 
interactions.  The cytoplasmic tail (residues 70-77) is implicated to play an 
important role in the binding of M1 to M2 (McCown and Pekosz, 2006).  M2 plays 
a role in stabilising the viral budding site by inducing negative membrane curvature 
at the budding site (Schmidt, Mishra, Wang, Degrado, et al., 2013).  Any mutation 
within the residues required for the interaction between M1 and M2 may inhibit 
IAV filament formation (Rossman et al., 2010).  Truncation at residue 70 of 
A/Udorn/72 M2 causes a loss of filament formation on the surface of cells infected 
with IAV and the loss of its interaction with M1 (McCown and Pekosz, 2006). Loss 
of filament formation has also been observed in mutations of M2 amphipathic helix 
(Rossman et al., 2010).  Residues 70-77 are also necessary for efficient production 
of viral particles, mutations at these residues have been shown to impair 
incorporation of vRNP into budding virions (Grantham et al., 2010). The 
cytoplasmic tail of M2 can also be phosphorylated (Hughey et al., 1995), 
ubiquitinated (Su et al., 2018) and has been shown to interact with: Annexin A6 
(Ma et al., 2012), Hsp40 (Guan et al., 2010), Calveolin-1 (Zou et al., 2009), 
TRAPPC6AΔ (Zhu et al., 2017), LC3 (Beale, Wise, Stuart, Benjamin J Ravenhill, 
et al., 2014), Caspase (Zhirnov and Klenk, 2009) and ATPase6 (S. Mi et al., 2010), 
though the functions of most of these modifications and interactions remain 
unknown.   
In the budding virus, M2 is localised to the plasma membrane, but is not associated 
with lipid rafts as the more abundant HA and NA proteins are (Zhang, Pekosz and 
Lamb, 2000).  M2 is thought to recruit vRNPs, which are complexed with M1, in 
order to package them within newly forming virions.  Moreover, M2 has the ability 
to induce negative plasma membrane curvature.  This is an essential requirement 
for viral budding, as without induction of this curvature, virions are unable to ‘pinch 
off’ host cells and subsequently continue infection.  It is this ability of M2 to induce 
such curvature that has been a focus of attempting to understand why certain strains 
of IAV can produce infectious viral filaments.  A role for M2 in filamentous virus 
formation has been well established but the cause remains unclear.  Roberts, Lamb 
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and Compans reported in 1998 the ability of the monoclonal antibody 14C2 raised 
against the ectodomain of A/Udorn/H3N2 M2 to inhibit the formation of viral 
filaments (Roberts, Lamb and Compans, 1998).  This phenomenon may be 
explained by the interference of membrane curvature by 14C2 or by M2 interacting 
with M1; however the discovery of cytoplasmic tail mutants by Beale et al in 2014 
being able to influence morphology also add weight to the importance of M2 in this 
phenotype.  Beale et al demonstrated the ability of the M2 cytoplasmic tail to bind 
to the mammalian ATG8 homolog, Microtubule-associated proteins 1A/1B light 
chain 3B (LC3), which enabled the virus to not only subvert cellular autophagy, but 
also affected the virus’s ability to form filaments. 
1.51 M2 and autophagy subversion 
IAV can subvert autophagy by the ability of specific residues within the CT of M2 
to block the fusion of autophagosome with lysosome.  Autophagy is part of the 
cellular protein degradation and recycling machinery.  In the normal pathway 
shown in Figure 6, proteins which have been marked for degradation through 
ubiquitination are engulfed by a forming double membrane phagophore, which 
itself is initiated by the action of ULK1 and class III PI3K complexes (Ndoye and 
Weeraratna, 2016).  In selective autophagy, p62 is able to bind to ubiquitin tagged 
proteins and chaperone them to the elongating phagophore wall.  p62 itself contains 
an LC3 interacting motif (LIR), allowing it to bind to LC3 (Pankiv et al., 2007).  
LC3 is the main marker used to study autophagy as it is crucial for autophagosome 
formation and closure of the phagophore into a double membrane autophagosome 
vesicle (Tanida et al., 2005; Mizushima and Yoshimori, 2007; Tanida, Ueno and 
Kominami, 2008).  After the closure of the autophagosome, LC3 is contained within 
the lumen in complex with p62 and tagged proteins.  LC3 is also present on the 
surface of autophagosomes (Kabeya et al., 2000), where it is essential for the 
subsequent fusion of the autophagosome to the lysosome containing the hydrolytic 
enzymes required for breakdown of the autophagosome contents including LC3 and 
p62 (McEwan et al., 2015).  Several small molecule inhibitors of various stages of 
autophagy exist, with compounds such as chloroquine and bafilomycin A1 blocking 
specifically the fusion of the lysosome to the autophagosome (Mizushima, 
Yoshimori and Levine, 2010).  In the context of IAV infection, this phenomenon is 
subverted by M2 (Gannagé et al., 2009).  The CT of M2 is known to contain a LIR, 
much the same as p62 (Beale, Wise, Stuart, Benjamin J. Ravenhill, et al., 2014).  
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This may create a twofold effect in the ability of M2 to allow the subversion of 
autophagy by IAV, thereby preventing viral protein degradation.  Firstly, M2 may 
compete for binding of p62 with LC3 through the highly conserved FVxI motif, 
which is contained in both M2 (91 – 94) and p62.  This motif is found in over 99% 
of unique M2 sequences (Squires et al., 2012).  Through competitive binding 
disrupting the LC3-p62 interaction, and the necessity of a LC3-p62 interaction 
required to degrade proteins through selective autophagy, this is one way in which 
M2 may disrupt the pathway, though this has not yet been proven.  Secondly, the 
binding of LC3 by the M2 LIR causes a distinct and striking relocalisation of LC3 
to the plasma membrane (Beale, Wise, Stuart, Benjamin J. Ravenhill, et al., 2014) 
(Figure 7).  This sequestering of LC3 away from the site of autophagy may deplete 
cytoplasmic LC3 which might otherwise be available for autophagy.  This may 
allow IAV to use autophagy machinery to enhance virion stability and budding. 
 
Figure 6 – Autophagy.  Image taken from Ndoye and Weeraratna, 2016 “Autophagy- An emerging 






Figure 7 – LC3 relocalisation during IAV infection.  Image is taken from Beale, Wise, Stuart, 
Benjamin J. Ravenhill, et al., 2014, and displays the distinct relocalisation of LC3 from freely 
cytoplasmic, to plasma membrane, upon infection with IAV. 
1.52 M2 and SUMO interactions 
SUMOylation is a post-translational modification (Hannoun et al., 2010), which is 
speculated to have an important role in maturation and assembly of influenza virus. 
SUMO (Small Ubiquitin-like Modifiers) are predominantly located in the cell 
nucleus; they conjugate to many proteins and regulate cellular processes such as 
transcription, cell-cycle progression and DNA repair (Domingues et al., 2015). 
SUMOylation is where SUMO is conjugated by an isopeptide linkage to a lysine 
residue by a small set of known enzymes.  
SUMOylation of a protein via an isopeptide linkage alone, does exert physiological 
consequences; however, through SUMO-interacting motifs (SIM) a SUMOylated 
protein gains the ability to control the interactions and function of other proteins 
and is one of the main consequences of SUMOylation (Minty et al., 2000; Yang 
and Sharrocks, 2010; Zhao et al., 2014).  SIM are less than 10 amino acids in length, 
they may contain phosphorylated residues and interact with SUMO via a specific 
surface groove (Kerscher, 2007).  Properties and requirements for a SIM are 
conserved, however the sequence required for one SUMO paralogue does differ 
from another despite reasonable similarity between paralogs (Namanja et al., 2012). 
The majority of SIMs have two main elements: a hydrophobic core consisting of 
three to four residues often being valine or isoleucine; and an acidic region of 
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glutamic acid or aspartic acid side chains, or phosphorylated serine or threonine 
residues.  SIM hydrophobic residues bind SUMO via β2 strand which causes 
extension of the β-sheet of the β-grasp fold. The parallel or anti-parallel orientation 
of SIM to the β-strand is controlled by binding of SIM acidic residues to basic ones 
on SUMO, this also has the effect of strengthening the interaction of SIM-SUMO. 
Because of the role of acidic residues, they are only required to be within close 
proximity to the hydrophobic core of the SIM which leads to even wider variation 
in SIM motifs (Hecker et al., 2006).  
Multiple proteins of IAV become SUMOylated during virus replication.  M1 is 
SUMOylated at K242 which is required for the interaction between M1 and RNP. 
A lack of M1 SUMOylation prevents the export of RNP (Wu, Jeng and Lai, 2011a). 
NS1 (Non-structural protein 1) is SUMOylated within its C-terminus at K70 and 
K219 which increases the stability of NS1 and promotes increased growth of IAV 
(Pal, Rosas and Rosas-Acosta, 2010). The N-terminal region of NP (Nucleoprotein) 
is SUMOylated at K4 and K7.  K7 Is highly conserved amongst the many strains 
and subtypes of IAV however it is not required for the survival of the virus. 
SUMOylation of NP, however, is essential for virus growth and the intracellular 
trafficking of NP its self (Chen et al., 2017).  Preliminary data suggests that the M2 
protein may also interact with SUMO, though this has not been previously 
examined.  
1.53 M2 and caspase cleavage 
The M2 CT contains multiple cellular protein interaction sites as described above.  
Situated at positions 87 and 88 are two aspartic acid residues, which function as the 
active resides of a conserved caspase cleavage site.  Previous studies have 
determined this ability of M2 to be cleaved by cellular caspases to be necessary for 
pathogenicity but not necessarily for replication in vitor (Zhirnov and Syrtzev, 
2009).  Viruses with a D87 mutation, rendering M2 uncleavable, still infected and 
replicated in chicken hosts and retained this trait, but with reduced mortality of the 
host (Zhirnov and Klenk, 2009).  However, the function of the caspase cleavage 







This thesis attempts to shed light on some of the more nuanced interactions of the 
cytoplasmic tail of M2, and how these may lead on to an influence on morphology 
of newly forming virions.  Data is presented on the presence of a SIM within the 
cytoplasmic tail of M2, and its effects studied.  Previously published data on the 
M2-LC3 interaction is expanded upon using M2 mutants which attempt to disrupt 
the LIR, the SIM, or both.  Morphology of viruses used for LAIV vaccine 
production are also evaluated with well-established confocal microscopy 
techniques.  Data and discussion presented in this body of work hopes to provide a 
basis for the continued study of the highly conserved cytoplasmic tail of M2, and 






































2.01 TISSUE CULTURE 
HEK-293T cells (human embryonic kidney), MDCK (Madin-Darby canine kidney) 
cells, A549 (adenocarcinomic human alveolar basal epithelial) cells, HeLa (human 
epitheloid cervix carcinoma) cells and HeLa HEX ATG8 knockout cells (Nguyen, 
et al., 2016) were grown in Dulbecco’s Modified Eagle’s Medium (P04-04510, 
DMEM, PAN Biotech., Aidenbach, Germany).  DMEM was supplemented with 
10% foetal bovine serum (P30-3306, PAN Biotech) and 1% penicillin/streptomycin 
(15140122, Gibco Life Technologies, Thermo Scientific, Loughborough, United 
Kingdom).  Cells were grown at 37°C in the presence of 5% CO2 and passaged to 
~80% confluency in appropriate flasks (T25, T75 or T175 – Sarstedt, Numbrecht, 
Germany) prior to splitting.  Once desired confluency was achieved, supernatant 
media was discarded, and cells were washed twice with warm PBS in order to 
remove residual culture media containing FBS.  Cells were then incubated in 0.25% 
Trypsin in PBS (P10-022100, PAN Biotech, Aidenbach, Germany) to facilitate 
detachment from the flask.  Once detachment had occurred, warmed supplemented 
DMEM was used to wash the cells down the flask, and collect them in to a 15 ml 
collection tube.  Cell suspension was then centrifuged at 1000 x g for five minutes 
at room temperature.  The supernatant media was then discarded from the resultant 
cell pellet, and the pellet was resuspended completely in supplemented DMEM to 
the desired volume.  To prepare a new cell culture flask for seeding, the appropriate 
amount of supplemented DMEM was placed in to the appropriate flask, and a 
volume of resuspended cell pellet was introduced. 
Cell lines were obtained from the American Type Culture Collection (ATCC) or 
the European Collection of Cell Cultures (ECACC).  Cells obtained from ATCC: 
HeLa (CCL-2), HEK 293-T (CRL-3216), A549 (CCL-185).  Cells obtained from 
ECACC: MDCK (84121903).  HeLa HEX cells were a kind gift from Michael 









2.02 CLONING OF M2 MUTANTS 
pCAGGS plasmid vector containing IAV M2 from H3N2 A/Udorn/307/1972 strain 
was described previously (Rossman, Jing, Leser, Balannik, et al., 2010).  Site 
directed mutagenesis was performed on this plasmid using New England BioLabs 
(NEB, Ipswich Massachusetts USA) Q5 Site-directed Mutagenesis Kit Protocol 
(product number E0554), primers were designed using NEBaseChanger v1.2.6 
(http://nebasechanger.neb.com/) and manufactured by Eurofins Genomics 
(Wolverhampton, United Kingdom).  I94M and V92S mutations were produced in 
pCAGGS M2 H3N2 A/Udorn/307/1972.  
gBlocks Gene Fragments were designed to produce mutants F91A, I94M, and 
FLAG-M2 consisting of 3 repeats of IAV M2 H3N2 A/Udorn/307/1972 residues 
87-97 with an N-terminal FLAG tag.  gBlock Gene Fragment manufactured by 
Integrated DNA Technologies (Integrated DNA Technologies, Leuven, Belgium), 
are double-stranded, sequence-verified genomic blocks consisting of EcoRI, XhoI 
restriction enzyme sites surrounding the mutant IAV M2 H3N2 A/Udorn/307/1972 
gene.  M2 mutants produced by PCR and gBlock fragments were digested using 
EcoRI (FD0274), XhoI (FD0694) (FastDigest, Thermo Scientific, Loughborough, 
United Kingdom), separated by agarose gel electrophoresis, extracted by QIAquick 
Gel extraction kit (28704, Qiagen, Hilden, Germany) and ligated into pCAGGS 
backbone using Anza T4 DNA Ligase (IVGN2104, Invitrogen, Carlsbad, 
California, USA).  The ligation product was transformed into NEB 5-alpha 
Competent E. coli (C2987I, NEB, Ipswich MA, USA) using their proprietary heat 
shock protocol.  E. coli were grown on Lysogeny broth (LB), agar, and ampicillin 
plates.  A single colony from each plate was grown overnight in 15ml LB with 
ampicillin, shaking at 200 rpm and 37°C.  Plasmid was recovered by mini-prep 
(K0502, GeneJET Plasmid Miniprep Kit, Thermo Scientific).  The concentration of 
plasmid stocks was measured by Implen (Munich Germany) NanoPhotometer N60 
and sequenced by Source Bioscience (Nottingham, United Kingdom).  Transfection 
quality DNA was produced by subsequent transformation and midi-prep of the 
plasmid (K0481, GeneJet Plasmid Midiprep Kit, Thermo Scientific), with the 
subsequent concentration determined by NanoPhotometer.  Plasmid was 
subsequently aliquoted and stored at -20°C, and sequence was confirmed using the 
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Sanger sequenceing service provided by Source Bioscience 
(http://www.sourcebioscience.com/) Nottingham, UK. 
2.03 VIRAL INFECTION  
A/Udorn/301/1972 (H3N2) was used in most experiments as previously described 
by Rossman et al., 2010.  A/PR/8/1934, PR8ΔM2 (V7-T9 +U148A) and PR8ΔM42 
(U115C) viruses were a kind gift from Professor Paul Digard at The Roslin Institute, 
University of Edinburgh and have been previously described (Wise et al., 2012).  
Seasonal LIAV immunisation strains produced by MedImmune of Liverpool, UK, 
were a kind gift from Dr. Oliver Dibben (MedImmune). 
For viral infections, cells were seeded in six well tissue culture plate at a number 
such to achieve ~85% confluency at point of infection.  IAV H3N2 
A/Udorn/301/1972 was diluted in to DMEM with no supplementation in order to 
provide a viral inoculum having a multiplicity of infection (MOI) of 3.  The growth 
media was removed from the cell monolayer, cells were washed twice with warm 
phosphate-buffered saline (PBS, pH 7.4) as to remove infection inhibiting serum, 
and the viral inoculum added.  Cells were then incubated for two hours at 37°C, 5% 
CO2, and agitated every 15 minutes.  After two hours, the innoculation media was 
removed and new fully supplemented media was applied.  Cells were incubated for 
24 hours post-infection at 37°C and 5% CO2, after which they were either lysed 
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Cells were seeded in six well tissue culture plate at a number such to achieve ~65% 
confluency at point of transfection.  Typically, 1 µg of DNA was used per 
transfection condition, up to a maximum amount of 5 µg of DNA per well of a six 
well tissue culture plate.  Cells were transfected using Lipofectamine 3000 reagent 
(L3000008, Invitrogen, Carlsbad, California, United States) for transient expression 
studies, and TransIT LT1 (MIR2304, Mirus Bio, Madison, Wisconsin, United 
States) for performing viral rescue of IAV from recombinant DNA (see sub section 
‘Mutant virus production’).  For both products, the manufacturer’s protocol was 
followed.  For transient expression studies cells were incubated for 24 to 48 hours 
at 37°C and 5% CO2, after which time they were either lysed with appropriate lysis 
buffer, or prepared for immunofluorescence microscopy. 
2.05 LYSIS 
For assays needing gentle lysis, a lysis buffer of 1% Thesit (88315, Sigma-Aldrich, 
St. Louis Missouri USA) in tris-buffered saline (TBS, pH 7.6) was prepared, with 
protease inhibitors (cOmplete Protease inhibitor cocktail, 11697498001, Roche, 
Sigma-Aldrich, St. Louis, Missouri, USA).  For harsher and more complete lysis, a 
buffer of 1% NP-40 (I8896, Sigma-Aldrich) and 1% sodium deoxycholate in TBS 
was prepared.  Incubation media (viral inoculum or transfection complex media) 
was removed, kept or discarded, and appropriate volume and type of lysis buffer 
was added to the well.  Cells were incubated in lysis buffer on wet ice for 15 minutes 
with occasional agitation.  Cells were then gently scraped down with a sterile pipette 
tip, and collected in to a 1.5 ml collection tube.  The lysate was centrifuged at 15,000 
x g at 4°C for ten minutes, after which time the supernatant was removed, aliquoted 
and stored appropriately.  The insoluble material was discarded. 
2.06 WESTERN BLOTTING AND IMMUNOPRECIPITATION 
For all immunoprecipitations, the Thermo Scientific Classic IP kit (26146, Thermo 
Scientific, Loughborough, United Kingdom) was used, and the manufacturer’s 
instructions were followed.  This includes the instructions for preparation of the 
elutions for protein gel electrophoresis.  Whole cell lysates were prepared for 
protein gel electrophoresis by the addition of 2 x Laemmli sample buffer (4% 
sodium dodecyl sulphate, 20% glycerol, 120 mM Tris-Cl pH 6.8, 0.02% w/v 
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bromophenol blue) in a 1:1 ratio with lysate.  β-mercaptoethanol was added to a 
final concentration of 5%, and samples were boiled at 95 to 100°C for ten minutes 
before being allowed to cool completely.  Samples were run on Biorad criterion 
TGX 4-12% Bis-Tris gels (3450124, Bio-Rad, Hercules, California USA) using the 
manufactures protocol and tank, in tris-glycine-SDS (25 mM Tris, 192 mM 
Glycine, 0.1% SDS, pH 8.3) running buffer.  Transfer on to PVDF membranes was 
performed using Bio-Rad (Hercules, California, USA) Trans-Blot Turbo RTA Midi 
PVDF Transfer Kit (1704272), following the manufacturer’s protocol.  PVDF 
membranes were blocked in 5% milk w/v in TBS-Tween (TBS plus Tween-20 
[Sigma-Aldrich] 0.1%) for 1 hour, before appropriate dilution of primary detection 
antibody in fresh blocking solution was applied overnight at 4°C with agitation.  
After which, membranes were washed three times in TBS-T before the addition of 
secondary horseradish peroxidase (HRP) conjugated antibody, diluted 
appropriately in TBS-T, incubated for 1 hour with agitation at room temperature.  
Membrane was then further washed three times with TBS-T and twice with TBS.  
Chemiluminescent development of the membrane was achieved using the Clarity 
Western ECL Substrate (1705060S, Bio-Rad) as per the manufacturer’s protocol.  
Developed membranes were then visualised on a Syngene G: Box chemi-XX6 
imager (Cambridge UK). 
2.07 IMMUNOFLUORESCENCE MICROSCOPY 
For immunofluorescense microscopy, cells were seeded in wells containing 22 x 22 
mm coverslips.  After appropriate assaying, cells were washed twice with PBS to 
remove debris, before fixing in 4% paraformaldehyde (PFA) for 20 minutes on wet 
ice.  PFA was then safely removed, cells were further washed twice in cold PBS to 
arrest fixation, and if required were permeabilised with 0.1% Trition X-100 (Sigma-
Aldrich, St. Louis Missouri USA) in TBS for 10 minutes.  Cells were then blocked 
using 1% bovine serum albumin (BSA) and 0.05% Tween in TBS for 1 hour.  
Blocking solution was then removed, and primary antibody diluted in blocking 
solution was added, and incubated for two hours to overnight at 4°C.  Then, primary 
antibody was removed, cells were washed four times with TBS, and secondary 
fluorescently conjugated antibody was added to the cells in blocking solution for 
two hours.  Cells were again washed four times with TBS, before two water washes 
to remove residual salts.  Coverslips were mounted on glass slides using ProLong 
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Gold Reagent containing DAPI (P36931, Invitrogen).  When ready for imaging, 
prepared glass slides were imaged on a Zeiss LSM880 confocal microscope.  Laser 
lines of nanometer wavelengths 405, 488, 561 and 633 were used to excite the 
relevant fluorophores attached to secondary antibodies (e.g. Donkey anti-Mouse 
AlexaFluor 488), or small molecules (e.g. DAPI to visualise dsDNA) and the 
resultant fluorescence was collected using an adjustable emission collection range 
when conducting standard confocal microscopy (range 380 nm to 750 nm).  When 
utilising the Airyscan capability of the LSM880, emission filters had to be chosen 
manually to accurately collect the correct fluorescence emission.  The available 
filter sets were: Band Pass (BP) 420 nm – 480 nm plus BP 495 nm – 550 nm; BP 
420 nm – 480 nm plus BP 495 nm – 620 nm; BP 495 nm – 550 nm + Long Pass 
(LP) 570 nm; BP 570 nm – 620 nm plus LP 645 nm. 
 
 
2.08 FLUORESCENCE POLARISATION  
Fluorescence polarisation was performed using a short FITC-labelled M2 peptide 
FITC-Ahx-DSHFVSIELE residue 88-97 (Biomatik, Wilmington Delaware USA) 
from the H3N2 A/Udorn/307/1972 strain at a concentration of 50 nM.  50 µl of 
distilled, sterile water was placed into each well of a black flat bottomed 96 well 
plate.  A serial dilution of the protein ligand was performed at the following staring 
concentrations: 4μM SUMO1/2/3 (Boston Biochem, [K-700]), 25 μM LC3A 
(Boston Biochem, [rhHis6-LC3/MAP1 LC3A, UL-430]), 25 μM LC3B (Enzo, 
Farmingdale, New York, USA [BML-UW1155-0500]) and 10μM Ubiquitin 
(Boston Biochem, U-530).  50 μl of 50 nM M2-FITC peptide was added and 
incubated for 10 minutes with the ligand.  The plate was imaged using BMG 
Labtech CLARIOstar Plate Reader, performing a top down fluorescence 
polarisation scan exciting at 490 nm and collecting emission spectra at 525 nm.  
2.09 MASS SPECTROSCOPY  
A T75 tissue culture flask of confluent HEK-293T cells was transfected with 
pCAGGS FLAG-M2 consisting of three repeats of IAV M2 H3N2 
A/Udorn/307/1972 residues 87-97 (IDT) using the transfection protocol described 
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previously.  Cells were lysed and immunoprecipitated using monoclonal IgG2b 
anti-Flag antibody (CSB-MA000021M0m, Cusabio CusAb, College Park, 
Maryland, USA) as previously described, with the following alterations:  Cells were 
lysed in 900μl of TBS plus Thesit lysis buffer.  10 ng of Flag antibody was used in 
the immunoprecipitation and 50 µl of sample buffer elution was used.  Sample was 
run on Bio-Rad Mini-Protean TGX Gels in Tris-Glycine-SDS running buffer.  The 
gel was run to ensure that all protein within the sample was within a single band 2 
cm into the gel.  Coomassie staining was performed on the gel, whereby the single 
dye front containing the proteins to be analysed was excised.  After excision, the 
band was stored in sterile distilled water and frozen at -20°C.  Subsequent 
preparation of the sample and mass spectroscopy was kindly performed by Kevin 
Howland at the University of Kent Biomolecular Science Facility.  
 
2.10 BIOINFOMATICS 
GPS-SUMO 1.0 (http://sumosp.biocuckoo.org/) SUMOylation prediction software 
was used to analyse the sequence of A/Udorn/1972 M2.  Influenza Research 
Database (https://www.fludb.org/) was used to compile and align 8588 unique 
sequences of IAV M2.  A Logo was then created using WebLogo 3.6.0 
(https://pypi.org/project/weblogo/).    
2.11 PROXIMITY LIGATION ASSAY 
Cells were washed and fixed using 4% PFA for 10 minutes on wet ice (as per 
‘Immunofluorescence Microscopy’, with blocking and diluent reagents taken from 
the Duolink PLA kit, DUO92101) and permeabilised using 0.1% Trition X-100 in 
TBS for 10 minutes.  Incubation in appropriate primary antibodies was conducted, 
before utilising the Duolink Proximity Ligation Assay (‘PLA’, Sigma-Aldrich 
[product DUO92101]) reagents and protocol, within which was contained 





2.12 MUTANT VIRUS PRODUCTION 
IDT gBlock fragments were designed for V92S, I94M, F91A, H90Y and H90S to 
contain the restriction sites ClaI and ApaI.  gBlock fragments and pHH21 
containing the A/Udorn/301/1972 M segment were digested with ClaI (FD0144), 
ApaI (FD1414)  (FastDigest, Thermo Scientific) and then processed in the same 
way as pCAGGS M2 mutant cloning to produce mutant pHH21 IAV M segment 
H3N2 A/Udorn/301/1972 mutant plasmids.  Below is ClustalOmega sequence 
alignment for indicated M2 mutants: 
 
Recombinant viruses were rescued using the method previously described by Fodor 
et al., 2007 using HEK-293T cells as initial viral producers, and MDCKs as whole 
virus replicators in co-culture.   Briefly, this process involves transfection of HEK 
293T cells with all eight reverse genetics, pHH21 based vectors containing inserts 
coding for each viral segment, plus relevant mRNA production, using the 
transfection reagent TransIT-LT1 (Mirus Bio, Madison, Wisconsin, United States).  
HEK 293T cells are grown in a six centimetre tissue culture dish in co-culture with 
MDCK cells.  Once confluency of the dish reaches ~80%, the transfection 
complexes are added to the cells.  The principle being that HEK-293T cells are 
efficient acceptors and translators of DNA via transfection and can produce the 
initial virions in this way.  MDCK cells are poor acceptors of DNA from 
transfection, but excellent acceptors of virus for infection and subsequent 
replication.  After 48 hours, or when significant cytopathic effect (CPE) from virus 
is seen, supernatant is harvested, clarified by centrifugation (≥14,000 x g for 15 
minutes), aliquoted and frozen at -80°C or used immediately.  This clarified 
supernatant should contain some viable virus at a low but unknown titre.  
Subsequently, T75 tissue culture flasks containing MDCK cells only can be 
infected with this passage zero (P0) rescue supernatant, then the resultant 
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supernatant containing expanded viral titre can be quantified using the plaque assay 
method. 
2.13 TRYPAN BLUE COUNTING 
Cells were trypsinised, added to the supernatant and centrifuged at 100g for 5 
minutes.  Cells were resuspended in serum free media and diluted 1:1 with 0.4% 
w/v trypan blue solution and incubated for 5 minutes.  Cells were counted using 
haemocytometer and the percentage viability calculated.  
2.14 ANTIBODIES  
Anti-M2 14C2 and polyclonal goat anti-Udorn antibodies were used as previously 
described (Rossman et al., 2010).  Anti-SUMO was obtained from Sigma Aldrich 
under the product code PRS3969 and Abcam (Cambridge, UK) under the product 
code antibodies ab11672.  Anti-Vimentin antibody was obtained from Cell 
Signalling Technologies (London, UK) under product code D21H3, as was anti-
CK2 (#2656), anti-VATPase (#13569), anti-Clathrin (#4796), and anti-EIF3a 
(#2538).  Anti-HA was obtained from the influenza A antisera panel from BEI (NR-
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3.0 M2 CT INTERACTIONS WITH SUMO DURING VIRUS 
ASSEMBLY AND BUDDING 
The M2 protein of IAV is a 97 amino acid long, membrane spanning protein which 
functions mainly as an ion channel to allow the acidification of the viral core during 
the initial stages of IAV infection, when the virus is contained within an endosome 
during entry.  Structurally, M2 exists natively as a homotetramer (Holsinger and 
Alams, 1991) and contains three main domains – the ectodomain from positions 1 
– 24, the transmembrane domain containing the pore through which protons flow 
from positions 25 – 43, and finally the cytoplasmic tail from positions 44 – 97 
(Schnell and Chou, 2008; Pielak and Chou, 2011).  Modifications of proteins within 
the cell through either covalent SUMO binding, or interaction, is known to play a 
crucial role in several processes, both in the uninfected cell and in the virally 
infected cell.  SUMO’s effect on target proteins is broad, influencing gene 
expression and repression (Gostissa et al., 1999; Müller et al., 2000; Girdwood et 
al., 2003), subcellular localisation (Sternsdorf, Jensen and Will, 1997; Chakrabarti 
et al., 2000; Kishi et al., 2003) and structural and functional stability (Bies, Markus 
and Wolff, 2002; Lin et al., 2003; Ghioni et al., 2005).  SUMO is known to play an 
advantageous role in viral infection, such as during Epstein-Barr virus infection 
(Adamson and Kenney, 2001) and during Ebolavirus infection (Chang et al., 2009), 
as well as during the host immune response (Shuai and Liu, 2003; Liu, 2004; Z. Mi 
et al., 2010).  Furthermore, SUMO modification is known to occur in the proteins 
of IAV, namely of the matrix protein, M1, at position K242 (Wu, Jeng and Lai, 
2011a) and the polymerase subunit PB1, the nucleoprotein NP and the non-
structural protein NS2 (Pal et al., 2011).  Additionally, IAV infection is known to 
increase global cellular expression of SUMO (Pal et al., 2011). 
The interaction of the cellular small ubiquitin-like modifier, SUMO, with IAV M2 
was predicted through bioinformatic analysis of the M2 sequence using a SUMO 
predictor, GPS-SUMO (http://sumosp.biocuckoo.org/) and confirmed using co-
immunoprecipitation, and further using an in-situ interaction assay, the proximity 
ligation assay (PLA).  Co-immunoprecipitation is a reliable method of studying 
protein-protein interplay, be they covalent links or weaker interactions, but is not 
without its technical drawbacks, such as disruption of the interactions during lysis.  
PLA is a more sensitive way to study these interactions, without disturbing the cell 
membrane through lysis, or disrupting the interactions. 
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3.01 The M2 CT contains a SUMO interacting region 
Early studies (data not shown) alluded to an interaction between the M2 protein of 
the IAV strain A/Udorn/72 H3N2 and the small ubiquitin like modifier of the host 
cell, SUMO.  To understand what part of M2 was responsible for this interaction, 
the M2CT sequence of A/Udorn/72 IAV was analysed using the GPS SUMO 
prediction software and the results are displayed in Table 1.  SUMO interaction 
denotes a non-covalent interaction between the sequence of interest and SUMO.  
SUMOylation refers to covalent linkage of SUMO to the region.  Here, interaction 
is specifically analysed and not covalent linkage, as M2 is not predicted to be 
SUMOylated.  Position 92-96 returns the part of M2 of most interest, with a ‘score’ 
of 50 or greater taken to be significant.  This provoked interest, as this overlaps with 
positions 91 – 94 of the M2CT, which has been studied by Beale et al., 2014 and is 
the viral LIR domain (Figure 8).  Position 91 is of particular note, as substitution 
for an alanine at this position results in a loss of LIR functionality. 
This region of the M2CT is highly conserved, with all strains retaining both the LIR 
and SIM as seen in the logo composition of Figure 9.  The conservation of residues 
91 – 97 points to an important role for this region of the M2CT with possible 
implications for the role of the LIR in SUMO interaction.  It is important to note 










Table 1 – Full length A/Udorn/72 H3N2 M2 contains several potential SUMO binding or 
interaction sites.  Bioinformatic predictions using GPS SUMO 1.0 of SUMO interacting regions or 








Figure 8 – The cytoplasmic tail of A/Udorn/72 H3N2 M2 contains many cellular interacting 
sites.  Amino acid sequence of the cytoplasmic tail region of the M2 protein from the A/Udorn/72 
H3N2 strain of IAV.  Detailing of the various characteristic sites are annotated.  Note the SIM 






Figure 9 - Logo comprised of BLAST of 8,588 IAV M2CT sequences from 82-97.  Unique IAV 
sequences were analysed through the Influenza Research Database (https://www.fludb.org/). 
WebLogo (https://pypi.org/project/weblogo/) was then used to produce the logo. 
 
Bioinformatic predictions of interactions of the M2 CT with SUMO and LC3 
provided a basis for further investigation.  These predictions then allowed point 
mutations to be designed within the M2 CT in order to specifically influence SUMO 












3.02 Mutations in the M2 CT are predicted to influence its interactions 
Using bioinformatic predictions detailed in the previous figures, it is possible to 
infer changes in interactions with cellular proteins, namely LC3 and SUMO, 
through point mutations, deletions or double point mutations.  GPS SUMO and 
previous literature was used to elucidate function-altering mutations (Table 2-3) 
which were then engineered into the pCAGGS vector for transient expression. 
Mutation Function 
H90S Deprotonated mimic 
H90Y Protonated mimic 
F91A Loss of LIR 
V92S Loss of SIM 
I94M Loss of LIR and loss of SIM 
Table 2 – Point mutations in the M2 CT and their predicted effects 
Table 3 - Both mutant transient expression vectors and viruses were produced (ref. M&M 
section once numbered).  The table shows bioinformatic predictions of SUMO and LC3 
interactions of the new mutant sequences.  Initially, point mutants were tested using SUMO 
interaction prediction software (GPS SUMO, available online at http://sumosp.biocuckoo.org/) and 
LIR interaction prediction software (iLIR, available online at http://repeat.biol.ucy.ac.cy/cgi-
bin/iLIR/iLIR_cgi).  These mutations were then engineered in to pCAGGS expression vectors using 
site-directed mutagenesis for transient protein expression studies in mammalian cell lines. 
M2CT mutants were produced by site-directed mutagenesis, informed by the 
bioinformatical predictions indicated in Table 1.  These plasmids encoding for point 
mutant M2 proteins, plus wild type M2 and a control vector (empty pCAGGS) were 
then transfected in to HEK-293T cells using TransIT-LT1, in combination with an 
LC3-GFP expression plasmid, in order to confirm an in vitro interaction through 
co-immunoprecipitation.  24 hours post transfection, the cells were lysed, and 
immunoprecipiatated using anti-SUMO and anti-GFP antibodies in order to 














Figure 10 – Mutations in the M2 CT affect interaction with LC3 and SUMO.  HEK-293T cells 
were co-transfected with pCAGGS vectors containing the genes for A/Udorn/72 H3N2 M2, or M2 
mutants V92S, F91A or I94M, and LC3 fused with GFP.  Cells were incubated for 24 hours, after 
which point they were lysed.  Figure indicates one blot from a triplicate repeat. 
 
M2 and all of the mutants are present in whole cell lysate at just under 16 kDa as 
shown, and lysates are loaded equally.  The IP SUMO elution shows faint positive 
banding in the M2 and F91A lanes, with slight presence in the V92S lane.  I94M 
shows no positive co-immunoprecipitation at all, and the mock lane is negative. 
M2 co-immunoprecipitates strongly with LC3-GFP as is known from previous 
studies (Beale, Wise, Stuart, Benjamin J. Ravenhill, et al., 2014), and there is 
presence too in the V92S lane, though slightly reduced, with the F91A, mock and 
I94M lanes being completely clear as predicted. 
Additionally, it can be inferred from the above blot that M2 is in an interaction 
complex with SUMO, and not a covalent linkage owing to the presence of a positive 
14C2 detection at just under 16 kDa.  SUMO has a molecular weight of ~12 kDa, 
therefore, a covalent M2-SUMO complex would produce a 14C2 banding pattern 
of closer to 25 kDa. 
Coimmunoprecipitation studies were informative in confirming bioinformatic data.  
To further characterise the interactions seen above, an ‘in-situ’ interaction assay 
was subsequently performed. 
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2.03 M2 co-immunoprecipitates with SUMO in transfection but not infection 
Interaction of M2 with SUMO is seen in transfection studies through co-
immunoprecipitation.  This method can be affected by various external factors in 
sample preparation, including lysis conditions, which can obscure weak non-
covalent interactions.  Whilst co-immunoprecipitation is a reliable study, using an 
‘in-situ’ interaction assay such as proximity ligation will show interactions using a 
more sensitive method of detection through nucleic acid based probes and 
enzymatic amplification.  To further characterise M2-SUMO interactions, PLA was 
performed using plasmid-based expression (Figure 11), and a more relevant 
infection system using mutant viruses (Figure 12).  Mutant viruses were produced 
using a reverse genetics based expression system as first described by Pleschka et 
al., 1996.  Eight plasmids encoding for the eight IAV genome segments were 
transfected in to a co-culture of HEK 293T cells and MDCK cells.  HEK 293T cells 
efficiently express proteins from a plasmid system, whilst MDCK cells readily 
become infected, and produce virus.  Co-culture supernatant was harvested and 
further amplified in MDCK cells, before viral titres were obtained in order for 
samples to be used for study.  Mutant IAV produced in this way was verified 















Figure 11 – Transiently expressed wild type M2 interacts more strongly with SUMO than the 
F91A mutant as analysed in-situ using PLA.  HEK-293T cells were co-transfected with pCAGGS 
vectors containing the genes for A/Udorn/72 H3N2 M2, empty pCAGGS (‘Mock’) or F91A for 24 
hours and then prepared for PLA using antibodies 14C2 and anti-SUMO.  Figure indicates one image 









Figure 12 – Wild type (Wt) M2 and mutants F91A and V92S interact at a similar level with 
SUMO, whereas the double SUMO/LC3 mutant I94M interacts more robustly.  A549 cells 
were infected with Wt (A/Udorn/72 H3N2), mutant (F91A, V92S or I94M) or mock infection for 
18 hours and then prepared for PLA using antibodies 14C2 and anti-SUMO.  Figure indicates one 
image from a triplicate repeat set. 
Co-immunoprecipitation of M2/mutants and SUMO was unable to be performed in 
viral infection (data not shown).  No banding patterns on Western blots were visible 
after co-immunoprecipitation was performed following viral infection with wild 
type virus or the rescued M2 CT mutants.  Immunoprecipitation conditions were 
altered, and differential pulldown antibodies were used (14C2, SUMO or 
polyclonal anti-Udorn), but no reliable results were obtained, unlike when M2 or 
mutants are transiently expressed alone.  Instead, proximity ligation assays (PLA) 
were used to deduce interactions in vitro.  The PLA uses the principle of two 
primary antibodies bound to two ligands being in close proximity, whereby a 
fluorescent signal can be produced using the provided secondary antibodies and 




interacting, then no signal will be produced.  Where M2 has been transfected as in 
Figure 11 wild type M2 is shown to have a higher number of foci per cell than 
F91A.  However, during viral infection (Figure 12) whilst the number of foci per 
cell are comparable for wild type and F91A; I94M and I94S have significantly 
increased numbers of foci per cell in comparison to wild type and an inverse 
relationship is shown for M2-SUMO binding between transfection and infection.  
This indicates that during viral infection, there are other factors at play in relation 
to how M2 is modified, interacts with SUMO, and what role an M2-SUMO 




















3.04 The binding of M2 to SUMO, but not LC3, is pH dependent 
The initial stages of infection involve the encapsulation of the entering virus in an 
acidified endosome.  This acidification has a range of effects, with the most 
prominent being the flow of protons through the lumen of the ion channel of M2 in 
order to lower the pH in the viral core, which itself causes a cascade of events 
leading to the uncoupling of vRNPs and the fusion of the viral membrane with the 
endosomal, allowing release of viral genetic material in to the cell cytoplasm.  
Histidine at position 90, well within the cytoplasmic tail region of interest in LC3 
and SUMO interactions, is highly conserved (Figure 9) and is able to be protonated 
at low pHs, though no effect of this protonation has been previously demonstrated.  
To mimic the low pH environments which the M2 CT experiences, and examine 
how this may influence LC3 and SUMO interactions, purified LC3 and SUMO 
proteins were mixed with a C terminus peptide of M2 (88–DSHFVSIELE–97) with 
a FITC label, in a fluorescence polarisation assay.  The output of this assay enables 



















Figure 13 – Binding of SUMO to an M2 C-terminus peptide is pH dependent, whereas binding 
to LC3 is not.  M2 C-terminus peptide (DSHFVSIELE) was obtained from Biomatik (Oxford, UK) 
labelled with FITC such to enable detection through fluorescence.  Values were collected using the 
Clariostar software, and data points analysed and plotted in Graph Pad Prisim.  Figure indicates one 
data set from a triplicate repeat set. 
 
Figure 13 shows the Kd of labelled M2 C-terminus peptide with SUMO, LC3 and 
the control protein Ubiquitin at physiological pH versus an acidic environment, 
such which may be found in an acidified endosome during the initial stages of IAV 
infecting a host cell.  Specifically, here the ability of residue H90 is studied to 
investigate potential protonation, which is predicted to occur at and below pH 6.4 
(Huyghues-Despointes et al., 2003).  The Kd of M2 C-terminus with SUMO1, LC3 
and Ubiquitin is of comparable magnitude at pH 5.2, however binding of M2 C-
terminus with SUMO1 and Ubiquitin at pH 7.3 seemingly does not occur, where it 
does for LC3 albeit with a relatively high Kd in relation to LC3’s binding at pH 5.2.  
It can be inferred that the ability of H90 to be protonated at acidic pHs plays an 
important role in SUMO and LC3 binding of the M2CT, considering the acidic 
environment of endosomes, the role of M2 as an ion channel, and the conservation 
of H90.  The data in Figure 13 also demonstrates ubiquitin binding potential, 




3.05 H90 protonation does not affect SUMO interaction during viral 
assembly  
In an attempt to further characterise the protonation deficient mutant H90S, PLA 
was once again conducted using this mutant virus in an infection model, probing 
for M2 and SUMO and quantifying foci.  Ammonium chloride is used to block the 
acidification of endosomes, and therefore prevent or attenuate protonation of H90 
in the wild type virus.  This would provide some insight as to whether protonation 
of H90, at least in the endosomal stages of assembly and budding, was required for 
SUMO interaction in the M2 CT.  Cells were infected with either wild type virus, 
the unprotonatable H90S mutant, or a mock infection, and allowed to incubate for 
18 hours.  Proximity ligation assays were then performed, and resultant images 






















Figure 14 – Endosomal acidification does not affect M2 interactions with SUMO.  A549 cells 
were infected with Wt (A/Udorn/72 H3N2), mutant H90S or mock infection for 18 hours in the 
presence or absence of ammonium chloride, and then prepared for PLA using antibodies 14C2 and 
anti-SUMO.  Figure indicates one data set from a triplicate repeat set. 
 
The lack of a protonatable histidine residue or the neutralisation of endosomal pH 
by the addition of ammonium chloride during infection causes no noticeable 
difference in the foci : cell ratio when analysing M2 / SUMO foci using PLA.  This 
suggests that SUMO interaction with the M2 CT is not influenced by H90 
protonation in endosomes during virus assembly.  H90 protonation may affect 
SUMO interactions during virus entry; however, the low quantity of M2 in the 





3.06 M2 can interact with the intermediate cellular filament Vimentin 
After data showing convincing interaction of M2 with SUMO, and literature 
supporting M2 binding of LC3 in the autophagy pathway, a mass spectrometry 
study of potential other interacting partners of the M2 CT was undertaken in order 
to investigate which SUMOylated cellular proteins M2 may be interacting with.  A 
protein expression plasmid was synthesised containing three repeats of positions 87 
to 97 of M2 from A/Udorn/72 H3N2 with a FLAG tag on the N terminus.  48 hour 
expression of this construct in HEK 293T cells was conducted, and subsequently 
processed using large scale co-immunoprecipitation using anti-FLAG antibody.  
After SDS PAGE purification, a sample was sent to Mr. Kevin Howland at the 
University of Kent School of Biosciences Biomolecular Science facility for mass 
spectrometry analysis. 
Table 4 - Selected mass spectrometry results obtained after transfection of HEK-293T cells 
with an expression vector containing M2(87-97)-FLAG3.  HEK293T cells were transfected with 
vector expressing residues 87 – 97 of the A/Udorn/72 H3N2 M2 protein fused to a FLAG tag for 48 















Figure 15 – M2 co-immunoprecipitates with the intermediate cellular filament Vimentin.  
Western blot showing results of a co-immunoprecipitation performed with antibodies to interacting 
proteins suggested by mass spectrometry.  HEK293T cells were transfected with A/Udorn/72 H3N2 
M2 and incubated for 48 hours, after which point they were lysed in Thesit lysis buffer, centrifuged 
at 12,000 x g for ten minutes at 4°C, and the insoluble pelleted material was discarded.  Co-
immunoprecipitation was performed with antibodies to Vimentin, Casein Kinase 2, V-ATPase 6V1, 
Clathrin and elf3a.  Eluates run on protein gel electrophoresis, and Western blotting performed.  
Membranes were probed with 14C2 to determine any M2 interacting partners.  A ‘mock’ was not 
performed, as WT (M2 in this case) is the control, and we are looking for differences compare to 
WT, and not the ultimate phenotype. 
Mass spectrometry analysis returned over 250 potential interactions, five of which 
are shown in Table 4 that were selected for further investigation by studying 
previous literature which had suggested links between the cellular proteins and 
SUMO interactions, SUMOylation and IAV infection and lifecycle, one of which 
being Vimentin (Wu and Panté, 2016).  Vimentin is an intermediate cellular 
filament involved in anchoring of cellular organelles, cellular structuring, and in the 
formation of aggresomes to mediate the degradation of aggregated proteins, often 
in the context of autophagy.  Antibodies to the positive hits were then used to 
perform co-immunoprecipitation of M2 transfect HEK293T cells, and the resulting 
elutions analysed by western blotting (Figure 15).  The resulting image shows M2 
and Vimentin co-immunoprecipitation, indicating a strong interaction, but no 
interaction was seen for the other candidates.  Interestingly, immunoprecipitated 
vimentin was not of the predicted molecular weight of SUMOylated vimentin, 
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indicating that M2 interacts not through a SUMO interaction with SUMOylated 
vimentin, but through another medium not investigated here. 
3.07 M2CT mutant viruses do not adversely affect cell viability and all 
replicate with similar kinetics 
Understanding the extrapolated effects of M2 mutations in whole viral infection on 
cellular survival, and replication capability of mutant viruses is crucial to 
determining if these mutations would be advantageous, either through a primary or 
secondary mechanism of M2 CT interaction.  If mutations interfering with SUMO 
interactions or LC3 binding confer greater cell mortality or replicate to significantly 
higher titres than a wild type virus, investigations in to viral hijacking of these 
cellular pathways would warrant significant and meticulous study, as any impact 
on human disease could be severe.  Cells were infected with indicated mutant 
viruses at 1 MOI for the viability and growth kinetics assays, and either analysed 
trough trypan blue exclusion for the former or plaque assay to determine time point 
titres for the latter. 
Figure 16 – Cell viability is broadly equal between wild type and mutant M2 viruses.  Bar chart 
showing percentage cell viability 18 hours post infection with 1 MOI of viruses A/Udorn/72 H3N2 
(wt), mutants H90s, I94M or V92S, or mock infection.  After infection in a 3.5cm dish for 18 hours, 
cells were washed with warm PBS, trypsinised, pelleted and resuspended.  Viability was determined 
by trypan blue exclusion counting, using a haemocytometer and handheld counter.  Graph is 




Figure 17 – Growth kinetics of wild type A/Udorn/72 H3N2 compared with M2 CT mutant 
viruses.  Line chart showing the viral titre in plaque forming units per mL (PFU/mL) at 24, 48 and 
72 hours post infection.  Viruses A/Udorn/72 H3N2 (Wt), or mutant viruses I94M, H90S, V92S or 
H90Y were allowed to infect A549 cells for 24, 48 and 72 hours at 0.01 MOI. Graph is indicative 
of data from a triplicate repeat set.  A ‘mock’ was not performed, as WT virus is the control, and we 
are looking for differences compare to WT, and not the ultimate phenotype. 
 
Cell viability assays shown in figure 16 demonstrate that mutant viruses have a 
negligible effect on cell survivability of IAV infection compared to both the wild 
type virus and mock infection. 
The line chart in figure 16 represents the growth kinetics of the mutant and wild 
type virus over the course of three days.  All of the mutant viruses replicate similarly 
to one another, suggesting that the protonation mutants (H90S/H90Y) and the 
LIR/SUMO binding/interacting mutants (I94M/V92S) display a slight reduction in 
replication capacity.  This attenuation of replication seen in the mutant viruses is 
recurrent and repeatable in other plaque assay investigations.  The wild type virus 
is shown to replicate and grow to one log greater titre than the mutants.  The data 
suggests that the intact functions of the wild type M2 CT may play a role in efficient 
IAV budding and replication, and that mutations which affect these functions 




3.08 M2-SUMO localisation is variable when mutations in the CT are present 
It is known that mutations in the M2 CT can affect viral assembly and morphology, 
and also from this study that M2 has the ability to interact with SUMO and LC3.  
To understand whether mutations specifically disrupting predicted SUMO 
interactions with the M2 CT cause a change in morphology of budding virus, or a 
change in cellular localisation of SUMO, confocal microscopy was performed using 
the generated mutant viruses and A549 cells.   
Four colour immunofluorescent microscopy was conducted, in order to visualise 
the distribution of A/Udorn/72 H3N2 proteins as a whole (namely HA, NA, M1 and 
NP which are detected well by the polyclonal anti-Udorn antibody), M2 itself (wild 















Figure 18 – Confocal microscopy images of M2 and SUMO distribution in infected cells.  A549 
cells grown on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 (wild type) or M2 
mutants H90S, H90Y, F91A, V92S or I94M and infection was allowed to proceed for 18 hours.  








Figure 18 demonstrates the differences in morphology of mutant viruses, and the 
change in distribution of M2 and SUMO across these viruses.  SUMO is normally 
found in greatest quantity in the nucleus, and this is evident in the wild type virus 
infection.  Long filaments in the green Udorn channel can be seen protruding from 
the infected cells, which is characteristic of A/Udorn/72.  M2 is mostly distributed 
to the plasma membrane, and the viral filaments contain significant amounts of 
SUMO, which is likely attributable to the fact that M1 is known to be SUMOylated, 
and M1 is the viral protein in greatest quantities.  H90Y and H90S display 
morphologies most similar to wild type, with arguably slightly more cytoplasmic 
M2 staining, which provides further indication that H90 mutations may not directly 
affect the ability of M2 to bind SUMO, as per previous figures.  Both V92S and 
I94M show far more cytoplasmic M2 staining than wild type virus.  F91A is 
noteworthy as having distinct M2/SUMO colocalised foci and completely lacking 
viral filaments, as has previously reported with the autophagy subversion defective 














3.09 M2 and CT mutants colocalise with LC3 and LAMP1 regardless of 
mutation in infection 
Mutations affecting the LIR of the M2 CT are known to, in certain circumstances, 
influence localisation of both LC3 and M2 in host cells.  Here we looked at if 
mutation of sites which affect both the LIR and the SIM can have the same effect 
on LC3 localisation and the subsequent progression of autophagy as a well-
established LIR mutants such as F91S (Beale, Wise, Stuart, Benjamin J. Ravenhill, 
et al., 2014).  pCAGGS vectors containing genes for indicated mutants were 
transfected in to A549 cells alongside a pEGFP vector containing lysosomal 
associated membrane protein 1 (LAMP) and a pCDNA vector containing LC3-























Figure 19 – The effects of cellular LAMP1 and LC3 localisation with M2. Using Lipofectamine 
3000, A549 cells were transfected with LAMP1-GFP, LC3-mCherry and either pCAGGS vectors 
containing the genes for A/Udorn/72 H3N2 M2, or M2 mutants V92S, F91A or I94M, or an ‘empty’ 











Figure 19 shows the induction and progression of autophagy by M2 and M2 
mutants.  M2 is seen predominantly at the plasma membrane of the cells, and with 
WT M2 a strong colocalisation between M2, LC3 and LAMP1 can be observed.  
Conversely, in the LIR mutant F91A, LAMP1 appears to colocalise strongly with 
LC3 but neither colocalise particularly strongly with M2.  In the SIM mutants V92S 
and I94M, LAMP1, LC3 and M2 localise well together, though with less LAMP1 
colocalization than with WT M2.  I94M appears to affect lysosomal formation, as 
the localisation of LAMP1 is far more cytoplasmic than punctate, indicating altered 
lysosomal formation.  I94M also appears to display more LC3 localisation to the 
plasma membrane than both F91A and V92S, suggesting that there be interplay 
between SUMO and LC3 binding and M2 localisation.  To attempt to determine 
what role the cellular autophagy machinery may be having on the behaviour of M2, 
M2 localisation and viral morphology were examined using HeLa and CRISPR 

















3.10 Aberrant morphology and subcellular localisation of viral proteins is 
seen when autophagy pathways are not present 
In the case of the M2 F91A mutant, which is unable to bind LC3, a distinct lack of 
filamentous virus is seen (Figure 18).  This study speculates that there may be an 
interplay between LC3 binding, SUMO interaction and M2, coalescing in affects 
on morphology.  Wild type HeLa cells are known to display the filamentous virus 
phenotype when infected with wild type A/Udorn/72 H3N2 virus, much like 
MDCK and A549 cells.  Using a CRISPR knockout HeLa cell line (in which all six 
human isoforms of LC3 have been knocked out), henceforth referred to as HEX, 
morphology studies using confocal microscopy and mutant viruses were conducted.  
The HEX cell line does not express any of the mammalian ATG homologue genes, 
which contain ATG8 (mammalian LC3 homologue), and therefore cannot undergo 
the process of autophagy.  This may have wide ranging effects on viral replication 
as a whole, but the proceeding figure focusses mainly on the localisation of M2 and 
SUMO within this system. 
HeLa and HEX cells were infected with the wild type viruses or mutants, incubated 
for 18 hours and prepared for confocal microscopy using polyclonal anti-Udorn, 




















Figure 20 – Confocal microscopy images of M2 and SUMO localisation in infected HeLa or 
HEX cells.  HeLa or HeLa ATG knockout cells (HEX) deficient in the ATG family of proteins 
(therefore unable to perform autophagy) were infected with 1MOI of either A/Udorn/72 H3N2 
(wt), F91A, H90S, H90Y, I94M or V92S mutant viruses. Image data is indicative of results seen in 
a triplicate repeat set.   Scale bar 5 µM 
 
In all infection scenarios, SUMO is found in the highest concentration within the 
nucleus of both wild type HeLa cells and HEX cells, with localisation also seen in 
areas also positive for viral protein, including viral filaments (Figure 20).  No 
significant difference was seen in SUMO colocalization with viral proteins when 
comparing the different mutants and cell types. Overall viral filament formation 
was reduced in HEX cells and the F91A mutant, consistent with the role of LC3 in 




















formation in all cells whereas I94M formed robust filaments even in HEX cells. 
This suggests that autophagy and SUMO binding both affect viral morphology. 
3.11 Morphology of budding M2 CT mutant viruses shows irregularity in 
quality and quantity of filaments produced as analysed by HA staining 
HA is the most abundant viral surface protein, and is uniformly present over the 
entire surface of IAV, in both the spherical and filamentous forms of the virus.  To 
both further confirm and qualify the ability of the mutant viruses to form 
filamentous virions we analysed the HA distribution specifically in mutant viruses 
at the later budding stages of infection.  A549 cells were infected with 1 MOI of the 
relevant viruses for 18 hours and prepared for confocal microscopy, staining with a 


















Figure 21 – Confocal microscopy images showing surface HA distribution in infected cells.  
A549 cells grown on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 (wild type) 
or M2 mutants H90Y, H90S, V92S or I94M, and infection was allowed to proceed for 18 hours. 
Image data is indicative of results seen in a triplicate repeat set.   Scale bar 5 µM. 
 
All of the mutant viruses appear to show slightly stronger cell surface HA staining 
in comparison to wild type virus (Figure 21).  In contrast to HeLa infections, all 
mutants displayed a somewhat filamentous phenotype (Figure 21).  Of note are 
V92S and I94M mutant viruses.  V92S shows unusual ring shaped staining patterns 
which are not observed in the wild type, or other mutants.  Some these appear in 
relation to budding filaments, and may be Archetti bodies (white arrow, V92S 
panel).  I94M appears hyper filamentous in comparison to wild type, similarly to 
















3.12 Mutant M2CT viruses display altered levels of viral protein 
incorporation 
As the M2 CT mutations affected virus replication and protein localisation, but not 
overall viral protein expression, we investigated if any of these affects were due to 
altered virus assembly.  This was achieved by looking at the levels of viral protein 
incorporation in to budded virions.  After determining no change in viral replication 
kinetics (but a reduction in overall viral capacity), and studying effects of cellular 
localisation with potential interacting partners, the levels of viral proteins of interest 
in budded virus were quantified.  This may give some insight in to whether the 
mutations in the CT of M2 have an effect on viral packaging and protein 
incorporation.  Cells were infected with wild type or relevant mutant viruses, 
supernatant harvested after 18 hours, protein levels standardised using BCA assay 






Figure 22 – Western blot of supernatant taken from infected cell culture.  A549 cells were 
infected with 1 MOI of A/Udorn/72 H3N2 (WT) virus, or mutants H90Y, H90S, V92S or I94M.  At 
18 hours post infection, supernatant was collected from infected cells to quantify viral protein levels 
in budded virus.  Blot is indicative of data seen in a triplicate repeat set.  A ‘mock’ was not performed, 
as WT virus is the control, and we are looking for differences compare to WT, and not the ultimate 
phenotype. 
HA and NP protein levels in H90Y are comparable to those of wild type, however 
interestingly M2 and M1 are totally undetectable (Figure 22).  I94M shows a 
marked increase in all levels of viral protein, especially M2 and NP, possibly 
indicating this mutation conferring an advantage in viral packaging, but with no 
discernible increase in infectivity.  H90S and V92S show comparable levels of viral 
protein incorporation.  The differing levels of protein incorporation in to newly 




3.13 Some M2CT mutants alter the distribution of vRNP in late infection 
M2 is known to interact with M1 through motifs in the cytoplasmic tail, and M1 is 
responsible for anchoring the viral surface proteins HA and NA, as well as forming 
an intermediary binding link between these external viral proteins and the vRNP in 
the viral core, though it is not known if the CT of M2 is a direct binding partner of 
vRNP, or if the M1-M2 interaction is indirectly responsible.  It is known however, 
that disruptions upstream of the mutations generated in this study do affect vRNP 
incorporation in to newly forming virions (McCown and Pekosz, 2005, 2006; 
Grantham et al., 2010).  To evaluate whether the mutant viruses produced in this 
study also have an effect on vRNP localisation in late infection, cells were infected 
with either wild type or mutant viruses, and incubated for 18 hours.  Cells were then 
















Figure 23 – A549 cells grown on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 
(wild type) or M2 mutants H90S, V92S or I94M, or a Mock infection media containing no virus, 
and infection was allowed to proceed for 24 hours.  Image data is indicative of results seen in a 







Figure 23 shows infected cells probed with anti-vRNP antibody to investigate 
cellular distribution of vRNP in the different mutant viruses.  All viruses show 
vRNP export from the nucleus, with both I94M and V92S showing the lowest 
remaining levels of vRNP localisation in the nucleus.  In contrast, H90S displays 
aberrant localisation of vRNP perinuclearly in globular like bodies of unknown 
function.  Interestingly, the wild type virus shows some vRNP staining within the 


















3.14 vRNP distribution in early infection (~5 HPI) displays defects in nuclear 
trafficking in certain M2 CT mutants 
As Figure 23 showed altered vRNP localisation late in infection, we also sought to 
determine if the M2 CT mutations affected early localization.  vRNP localisation 
was studied in the wild type and mutant viruses to determine its distribution in the 
infected host cell.  Cells were infected with relevant viruses and prepared for 









Figure 24 – Confocal microscopy images showing vRNP distribution 5 HPI.  A549 cells grown 
on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 (wild type) or M2 mutants H90S, 
V92S or I94M, or a Mock infection media containing no virus, and infection was allowed to proceed 
for five hours.  Image data is indicative of results seen in a triplicate repeat set.  Scale bar 10 µM. 
Figure 24 shows A549 cells infected with indicated virus and stained at five hours 
post infection.  Notably, most of the mutant viruses display distinct nuclear 
localisation of vRNPs compared to wild type virus.  V92S shows this localization 
most clearly, with the majority of vRNP being localised to the nucleus.  This 
suggests that the mutants may be delayed in vRNP nuclear export compared to WT 








3.15 vRNP distribution in very early infection (~1HPI) is not greatly affected 
by mutations in the M2 CT 
As the M2 CT mutations affect vRNP trafficking late in infection we investigated 
if the mutations also affected uncoating and early trafficking of viral proteins 
within the host cell.  vRNP uncoating and release is essential for the propagation 
of IAV, as the genetic material of infecting viruses must reach the host cell 
nucleus for the progression of infection and the production of progeny virions.  To 
investigate uncoating and vRNP trafficking cells were incubated with relevant 
virus for one hour post infection.  After the incubation, cells were prepared for 









































Figure 25 – Confocal microscopy images showing vRNP distribution in early infection.  A549 
cells grown on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 (wild type) or M2 
mutants H90S, V92S or I94M, or a Mock infection media containing no virus, and infection was 
allowed to proceed for one hour.  Image data is indicative of results seen in a triplicate repeat set.  
Scale bar 10 µM. 
At one hour post infection, all viruses had entered the cells, with some vRNPs 
localised at or near the plasma membrane and some vRNPs within the nucleus 
(Figure 25).  The H90S mutant virus displays some vRNP clustering, whereas the 
V92S mutant appears to show greater cytoplasmic distribution.  To further evaluate 
any differences in early entry and uncoating between the wild type virus and mutant 
viruses, a further study of M1 and HDAC6 was conducted. 
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3.16 Mutations in the M2 CT appear to affect uncoating as qualitatively 
analysed through M1 staining, but localisation of HDAC6 is unaffected 
HDAC6 is an enzyme with a wide array of functions, not only its deacetylation 
activity, most notably of tubulin (Hao et al., 2013), but also playing a key role in 
the formation of aggresomes.  Aggresomes are defined by the formation of a 
vimentin ‘cage’ around a collection of proteins which have been marked by 
degradation by autophagy for example, and through ubiquitinylation (Johnston, 
Ward and Kopito, 1998).  IAV is known to incorporate ubiquitin chains in to the 
budding virus, and it is speculated that this causes recruitment of HDAC6 to the 
uncoating virion in the late endosome, and vRNPs are released in to the cytoplasm 
in an HDAC6 dependent manner (Banerjee, Miyake, Nobs, et al., 2014).  To 
analyse if the M2 CT mutant viruses produced for this study had an effect on viral 
uncoating, A549 cells were infected either with wild type virus, or with mutant 
viruses as indicated.  After five hours of incubation post infection, cells were 























Figure 26 – Confocal microscopy images showing HDAC6 distribution in infected cells 5 HPI.  
A549 cells grown on glass coverslips were infected with 1 MOI of A/Udorn/72 H3N2 (wild type) 
or M2 mutants H90S, V92S or I94M or a Mock infection inoculum containing no virus, and infection 
was allowed to proceed for five hours.  Image data is indicative of results seen in a triplicate repeat 











HDAC6 localisation appears to be unaffected in the mutant virus samples when 
compared to wild type virus (Figure 26).  Small foci of HDAC6 are seen, and some 
colocalisation of M1 and HDAC6 is seen in the wild type, I94M and V92S mutant 
infections.  In these viruses, some foci of M1 staining are present, indicating 
endocytosed virus, and some diffuse M1 staining is seen, indicating viral uncoating.  
However, the H90S mutant virus shows comparably little internalised virus as 
indicated by M1 staining, and aggregated ‘spindle-like’ presence of M1 on the cell 
surface.  This may be an indication of a defect in viral entry for this mutant.  For 
the V92S mutant, once again, the ‘spindle-like’ staining is visible on the cell 
surface, however there is far more virus internalised than with H90S.  This suggests 
that the SIM mutants have a late stage vRNP trafficking defect and not an entry 
























The polysemy of the cytoplasmic tail of M2 has been shown through assays 
investigating its interaction with the key autophagy protein LC3; the small 
ubiquitin-like modifier SUMO; and mutations which may affect M2’s interaction 
with other viral proteins.  The highly conserved nature of the M2 CT points to the 
crucial role in both the entry, replication, and budding stages of the IAV lifecycle.  
The investigations herein demonstrating a still poorly understood role for the 
repeatable, but non-covalent, interaction of M2 with SUMO via a motif at the C 
terminal of the 97 amino acid protein, which is affected by point mutations targeting 
the LIR and the SIM.  These point mutations are producible in whole virus through 
reverse genetics rescue, and show ability to replicate albeit with lower viral titres 
than the wild type A/Udorn/72 H3N2 virus.  Studies with LIR mutant viruses and 
with WT and SIM mutants in HeLa cells deficient in autophagy demonstrate 
dysfunctional M2 and SUMO localisation.  Analysis of viral budding through 
surface HA staining of cells infected with wild type or mutant viruses show altered 
viral morphology when the LIR or SIM domains are disrupted.  Point mutations in 
the M2 CT also cause changes in viral protein packaging as seen in western blotting 
studies, and clearly influence the distribution of vRNPs within infected cells 
through an unknown mechanism.  Furthermore, viral entry and uncoating is affected 
by M2 CT point mutations in a conserved protonatable histidine reside. 
Subsequent work has looked at how viral filament formation is affected by: M2 
interactions with the intermediate filament protein vimentin; the behaviour of an 
alternative splice variant of M2; and autophagy interactions of viruses used in 
seasonal intranasal vaccines.  
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3.2 M2, ALONG WITH OTHER M SEGMENT PROTEINS AND 
VIRAL SURFACE ANTIGENS, CAN INFLUENCE CELLULAR 
PROCESSES AND VIRAL MORPHOLOGY 
Previously in this study, the effect of various mutations in the cytoplasmic tail 
region (positions 91 to 97) of the M2 ion channel protein of A/Udorn/72 H3N2 have 
been produced for analysis by transient expression in a plasmid vector, and in whole 
virus through generation by reverse genetics.  Mutations were identified 
bioinformatically which would affect the ability of the M2 CT to bind to the 
autophagy protein, LC3, through the LIR at positions 91 – 94, and the SIM at 
positions 91 – 96.  The data gathered demonstrated moderate colocalisation of M2 
with LC3 specifically, with additional convincing data for the interaction of M2 
with SUMO.  Therefore, we attempted to investigate further factors which may 
modulate the overall interactions of the M2 CT and the regulation of viral filament 
formaton, through an alternative splicing variant of the M segment, the organisation 
of the intermediate cellular filament Vimentin (as demonstrated to interact with M2 
in table 4 and figure 15), and the behaviour of virus strains used to produce seasonal 




3.21 An alternative splice variant of M2 displays distinct colocalisation with 
LC3 
All IAV subtypes have the capability to produce alternative splicing variants of 
segment seven, the ‘M’ segment of the viral genome.  Though alternative splicing, 
some strains such as A/PR8/33(H1N1) can produce an ‘M2-like’ ion channel 
protein which can functionally compensate for M2 but contains a novel ectodomain 
of unknown function (Wise et al., 2012).  However, M42 is localised distinctly 
cytoplasmically, in contrast to the highly plasma membrane localisation of M2.  
M42 is largely retained within the Golgi apparatus during infection as seen in the 
original report by Wise et al., 2012, and its localisation appears similar in this report 
in a plasmid based expression system.  Newly investigated below is the propensity 
of M42 to highly colocalise with LC3, in a fashion surpassing that of M2.  HEK 
293T cells were transfected with plasmids encoding for LC3b-mCherry and either 
pEGFP-M42 or pEGFP-M2 from the PR8 strain of IAV.  Cells were prepared for 






























Figure 27 – Colocalisation of M2/M42 with LC3.  HEK293T cells were grown on coverslips 
treated with poly-L-lysine before transfection.  Cells were transfected using TransIT-LT1 with 
mCherry-LC3b and either GFP-M2 (top), GFP-M42 (middle) or empty vector (bottom). Image data 
is indicative of results seen in a triplicate repeat set.   Scale bar 20 µM. 
 
DAPI LC3-mCherry Merge M2-GFP 
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DAPI LC3-mCherry Merge 
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Figure 27 shows the difference in localisation between M42 and M2 of A/PR/8/34 
H1N1 (‘PR8’) and LC3.  LC3 in the negative control shows diffuse cytoplasmic 
localisation, and this appears similar in the M2 images, with only small foci 
observed.  However, M42 localises distinctly with LC3, and is seen in significantly 
lower quantities at the plasma membrane in comparison to M2.  This phenomenon 
is yet to be understood, as all previous literature and data point to, and confirm, that 
an LIR in the CT of M2 is responsible for binding to and sequestering LC3.  M42 
contains the same LIR-containing CT as M2 and thus, would be predicted to 
associate with comparably LC3, though the novel ectodomain may affect protein 




















3.22 PR8 ΔM2 and ΔM42 viruses display altered budding patterns 
The PR8 virus is a H1N1 strain which does not produce filamentous particles in 
vitro.  Wild type A/Puerto Rico/8/34 (H1N1) produces both M2 and M42 in normal 
infection, and a number of other IAV strains have been identified as producing, or 
likely to produce, M42 from alternative splicing of segment 7 (Wise et al., 2012).  
As demonstrated by Wise et al. and previously in this study (figure 27), M42 
localises strongly intracellularly at the Golgi apparatus, with less plasma membrane 
distribution than M2.  To investigate if the enhanced association between M42 and 
LC3 affects viral morphology we infected A549 cells with wild type A/Puerto 
Rico/8/34 (H1N1), or the PR8 splicing mutant viruses PR8ΔM2 (producing only 
M42) or PR8ΔM42 (producing only M2) and evaluated viral morphology.  Samples 




































Figure 28 – Viral morphology comparison between cells infected with wild type PR8, 
PR8ΔM42 or PR8ΔM2.  A549 cells grown on glass coverslips were infected with 1 MOI of 
A/Puerto Rico/8/34 (H1N1), PR8ΔM2 (producing only M42) or PR8ΔM42 (producing only M2), 
and infection was allowed to proceed for 18 hours.  Image data is indicative of results seen in a 





Wild type PR8 displays morphology consistent with previous publications – diffuse 
positive plasma membrane staining for HA, with some bacilliform budding present 
and few membrane aggregates (Figure 28).  PR8ΔM42 shows distinct punctate 
staining of the plasma membrane, with few ‘halo-like’ structures on the cell surface, 
and no discernible bacilliform virus.  PR8ΔM2 stains very evenly for HA, and 
shows more positive HA staining intra- and peri-nuclearly, with a further, large 
(~10 µm) circular structure.  The perinuclear aggregration seen here and with M42 
and LC3 (Figure 27) may indicate formation of viral induced aggresomes.  This 
data suggests a differential and integral role for both M2 with M42 in the budding 





3.23 M2 within cells causes vimentin condensation, an indication of 
aggresome formation, and this is not affected by M2 CT mutations 
Data has been presented in this study which points to the interaction of M2 with the 
intermediate cellular filament vimentin, through mass spectrometry analysis and 
co-immunoprecipitation assays.  Vimentin is known to be involved in the formation 
of vimentin ‘cages’, which form as part of the aggresome complex during the 
process of unwanted protein degradation, such as during autophagy.  M2 is known 
to contain an LC3 interacting region in its cytoplasmic tail, and through this it is 
able to interact with the process of autophagy.  In addition, data in Figures 27-28 
suggest that M2 splice variants may induce aggresome formation.  To investigate 
whether M2, M42 and the generated M2 CT mutants can influence the arrangement 
of vimentin within the cell, HEK 293T cells were transfected with plasmids 
encoding for WT IAV A/Udorn/72 H3N2 M2, M42 or M2 CT mutants, and a 
pSmOrange-Vimentin vector.  Cells were incubated for 24 HPI, and then prepared 




























Figure 29 – Confocal microscopy images of transiently expressed A/Udorn/72 H3N2 M2 CT 
mutants stained for M2 and Vimentin.  HEK293T cells were grown on coverslips treated with 
poly-L-lysine before transfection.  Cells were transfected using TransIT-LT1 with pSmOrange-
Vimentin and either ‘wild type (WT)’ M2 from A/Udorn/72 H3N2, M42 or indicated M2 CT mutant.  
Cells were allowed to grow and express for 24 hours.  Image data is indicative of results seen in a 




Reorganisation of vimentin superstructure within the cell is known to be one of the 
indicators of aggresome formation, as the proteins undergoing degradation and 
recycling are bound by interweaved strands of vimentin, known as a vimentin cage.  
Furthermore, vimentin is known to play a role in facilitating the early stages of IAV 
infection, influencing the acidification of late endosomes and their trafficking, both 
of which are necessary for efficient IAV replication (Wu and Panté, 2016).  The 
organisation of vimentin was studied using a fluorescently tagged construct, 
vimentin-pSmOrange, and antibody labelling of transiently expressed M2, M42 or 
M2 CT mutants.  Compared to the empty vector mock transfection, vimentin 
undergoes dramatic reorganisation in all of M2 conditions, even when the CT is 
mutated to remove LC3 or SUMO binding (Figure 29).  Condensation of vimentin 
is hard to define at this resolution and with these assay parameters and so the 
interpretation of this reorganisation is difficult to define.  However, in the presence 
of M42, vimentin forms a cage like structure circling aggregated M42 proteins.  
This strongly suggests that the aberrant trafficking and localisation of M42 results 
in the formation of aggresomes that contain M42, LC3 and are surrounded by a 
vimentin cage.  This could explain the significant changes seen in virus assembly 




3.24 HA sequences from LAIV strains 
In addition to the M proteins, HA has also been shown to modulate viral 
morphology, possibly though manipulation of host cell autophagy (Jin, Leser and 
Lamb, 1994; Zhirnov and Klenk, 2013).  We investigated the impact of subtle 
variations of HA on viral morphology and autophagy by using historic LAIV strains 
that all retain the same M1 and M2 proteins, but have subtle variations in HA.  The 
donor IAV backbone is from A/Ann Arbor/6/60 (H2N2) which should produce 
spherical virions based on the M1 sequence.  All the internal genes and the matrix 
proteins are identical in the LAIV strains, with only variations in HA and NA. 
Figure 30 shows an amino acid sequence alignment produced using NCBI’s 
BLAST alignment tool.  Regions of conservation are red, regions of variance are in 
blue, and insertions are in green.  Many of the strains have highly related HA 





























































Figure 30 – Amino acid sequence alignment of full-length HA from indicated LAIV strains. 
Produced using the Basic Local Alignment Search Tool found at 
https://blast.ncbi.nlm.nih.gov/Blast.cgi.  Regions of variance are in blue, conservation in red, and 
insertions in green. 
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3.25 HA variants affect M2 localization and viral filament formation 
As demonstrated previously in this study, the M segment proteins and their 
interactions have a significant effect on M2 localisation, and therefore the 
morphology of budding virus.  Subsequently, we have used a collection of  LAIV 
strains to investigate the role of subtle variations in HA which may influence viral 
and cellular protein localisation and viral morphology.  These viruses are all 
produced using the same MDV backbone, with alternative H and N genomic 
segments, producing a range of HA and NA surface antigens, eliciting different 
immune responses in vaccinated patients to respond effectively to seasonally 
circulating IAV. 
With well reported and well characterised mutations of the matrix proteins, both in 
pre-existant literature and in this report, it is important to explore what other factors 
may influence filamentous IAV morphology.  Seasonal LIAV immunisation strains 
were obtained from MedImmune and analysed through infection and 
immunofluorescent confocal microscopy.   
The confocal images in figure 31 show interesting morphology between various 
candidate vaccine strains in A549 cells.  A549 cells were infected with the LAIVs 
and probed for HA and M2, with or without cell permiabilisation to better 
understand surface distribution of HA and M2 (no data for Victoria permiabilised).  
Unlike previous images in this report of A/Udorn/72 H3N2, which produces both 
classical spherical virions, and mostly well formed, straight and undisrupted 
filaments, some of the vaccine strain viruses produce aberrant, tangled 
accumulations of HA-positive foci, though some, such as South Dakota, produced 
extensive filaments and others, such as Victoria, produced minimal filaments. 
All LAIV strains, barring Victoria, display large positively HA straining aggregates 
on the cell surface, with differing localisation of M2 for all strains, with some 
strains, such as Uruguay, producing M2 perinuclear foci similar to that seen with 
M42.  This suggests, that subtle variants in HA can indeed alter M2 localisation and 
viral morphology, despite possessing the same M1 and M2 proteins.  Unfortunately, 
analysis of HA sequences did not identify any obvious variants that could explain 
this difference.  In addition, some strains exhibited nuclear M2 staining, though the 

































M2 HA DAPI Merge 




































Figure 31 – Confocal microscopy images of LAIV infected A549 cells.  A549 cells grown on glass 
coverslips were infected with 1 MOI of MedImmune vaccine strain viruses ‘Bolivia v8’, ‘South 
Dakota’, ‘Uruguay’ or ‘Victoria’, and infection was allowed to proceed for 18 hours.  Image data is 





3.26 LAIV strains induce LC3 puncta and M2 localises to the plasma 
membrane 
M2 localises to the plasma membrane in the model strain A/Udorn/72 H3N2 used 
extensively in this study.  As HA variations in the LAIVs affect M2 localisation we 
then investigated if alterations in autophagy induction may be responsible.  LAIVs 
were used to infect A549 cells and after 18 hours the cells stained for LC3 and M2. 
All the LAIV vaccine strains, produced using a donor virus backbone based on the 
A/Ann Arbor/6/60 IAV with HA and NA variations, still appears to induce 
autophagy through the formation of LC3 puncta (Figure 32).  Strains Bolivia v8, 
Perth and South Dakota induce larger and more robust LC3 puncta, with Bolivia v8 
displaying distinct colocalisation of M2 with LC3, interestingly these strains tended 
to produce more aggregated M2/HA foci and more robust filaments in Figure 31.  
Bolivia v4 induces smaller LC3 puncta, with less colocalisation with M2.  
Interestingly, Bolivia v4 shows less M2 overall at the plasma membrane than other 
strains, though the significance of this is not known. 
As with A/Udorn/72 H3N2, the CT of M2 in the MDV strain also contains an LIR, 
and such the M2 expressed by all LAIV strains would predict to interact with LC3.  
Thus, the differences in autophagy activation, M2 localisation and colocalisation 
with LC3, and viral filament formation are likely due to subtle differences in 











Figure 32 – M2 and LC3 localisation in LAIV infected A549 cells.  A549 cells grown on glass 
coverslips were infected with 1 MOI of MedImmune vaccine strain viruses ‘Bolivia v4’, ‘Bolivia 
v8’, ‘Perth’ or ‘South Dakota’, and infection was allowed to proceed for 18 hours.  Image data is 


















We have demonstrated the ability of the alternative splice variant of M2, M42, to 
affect subcellular localisation and LC3 interaction whilst still retaining a genetically 
identical cytoplasmic tail to M2.  M42’s robust colocalisation with LC3 suggests 
that the ectodomain may affect trafficking of the protein throughout the cell and the 
ability to bind LC3, resulting in the formation of peri-nuclear aggresomes.  This 
variation when studied in whole virus infection also causes both a change in the 
morphology of budding virus, and a distribution in positive surface HA staining in 
both A/PR8/34 H1N1 viruses which express either M2 alone or M42 alone.  In PR8 
at least, this suggests that differential expression of M2 and M42 significantly 
affects the budding of IAV from host cells. 
In revisiting the A/Udorn/72 H3N2 M2 and M2 CT mutants in transient expression 
studies in relation to vimentin, a considerable reorganisation of this intermediate 
cellular filament is seen.  This may be indicative of protein degradation pathways 
being altered in an M2 CT dependent manner, which would require further 
investigation, owing to vimentin reorganisation playing a role in the formation of 
‘vimentin cages’ during aggresome formation, as was seen with the splice variant 
M42.  Vimentin reorganisation also plays a role in the epithelial to mesenchyme 
transition (Mendez, Kojima and Goldman, 2010) and is known to have a role in the 
IAV lifecycle (Wu and Panté, 2016). 
The LAIVs used to immunise against seasonal IAV strains keep the same viral 
backbone (A/Ann Arbor/6/60), with HA and NA proteins swapped in and out for 
immunogenicity.  LAIV strains displaying varying HA surface proteins showed a 
wide and varied range of budding morphologies, notably with the formation of large 
tangled aggregates on the surface of infected cells.  Localisation of M2 also appears 
altered as was the initiation of autophagy, seen through LC3 puncta, with Bolivia 
v8 and Perth strains particularly adept at inducing autophagy.  This demonstrates 


































Through this investigation, the broad and promiscuous nature of the M2 ion channel 
has been investigated in regards to its influence on the morphology of budding IAV, 
its interaction with the autophagy protein LC3; its novel interaction with the small 
ubiquitin-like modifier, SUMO; further characterisation of the interaction of M42, 
an M segment splice variant, with LC3; the ability of M2 and M2 CT mutants to 
affect Vimentin reorganisation; and the effect of HA variability as used in LAIV 
strains to alter viral morphology. 
Results presented in this body of work further characterise the nature of the 
cytoplasmic tail of the M2 protein of the influenza A virus.  Further confirmation 
of the role of the M2 CT in binding to LC3 and the influence that various mutations 
have on this interaction have been studied.  Furthermore, a novel interacting partner 
for the M2 CT has been proposed, SUMO.  Data has shown that the M2 protein 
when expressed alone has the ability to interact with the Small Ubiquitin-Like 
Modifier, SUMO, expressed by the host cell, and that this interaction is not covalent 
(i.e. it is distinct from SUMOylation which occurs to cellular proteins and other 
IAV proteins, such as M1 (Wu, Jeng and Lai, 2011a)).  The SUMO interaction is 
mediated by a proposed SUMO interaction motif, SIM, within the cytoplasmic tail 
of M2 and that this SIM overlaps with the LC3 interacting region, LIR.  Initially, 
bioinformatics predictions identified this region, and through transient expression 
studies in HEK293T cells SUMO was shown to co-immunoprecipitate with M2 
(figure 10, page 51).  To further characterise this phenomenon, mutations were 
made using the residues indicated by the aforementioned bioinformatics.  These 
mutations took in to account the already published data on the LIR, and not only 
set out to characterise the SIM, but also if this had any link to LC3 binding, M2 







4.01 The presence of a SIM in the cytoplasmic tail of the IAV ion channel M2 
Not only was the interaction of SUMO confirmed with various mutant M2 proteins, 
and the wild type M2 protein, classically using co-immunoprecipitation, and PLA 
were also utilised to give an ‘in-cell’ understanding of interaction, and the 
localisation of this interaction.  M2’s interaction with SUMO was seen to be broadly 
perinuclear, concurring with previously published literature regarding the 
distribution of SUMO, as cellular SUMO is present in greatest quantities within the 
nucleus of mammalian cells (Johnson, 2007).  Speculation is still to be made on 
what role the SIM in the M2 CT may have.  Referring to M2’s ability to bind and 
sequester LC3, enabling the subversion of autophagy (Beale, Wise, Stuart, 
Benjamin J. Ravenhill, et al., 2014), it is possible that the SUMO interaction with 
the M2 CT could function in disrupting the interaction with LC3, affecting 
autophagy progression.  In Figure 10 (page 51), F91A shows a good retention of 
SUMO interacting ability, comparable to that of the wild type, but a complete loss 
of LC3 binding.  This is confirmed by the western blot in Figure 10 (page 51); 
however it is observed that for a slight drop in expression of F91A, an inverse 
increase in SUMO co-immunoprecipitaion is seen compared to the wild type.  I94M 
and V92S also show correlating immunoprecipitation data, validating the prediction 
by GPS SUMO.  However, when using the ‘in-cell interaction assay’, PLA, the 
foci/cell ratio for F91A interacting with SUMO was considerably lower than wild 
type M2.  This finding suggests that, whilst transiently expressed F91A may retain 
normal interactions with SUMO, interactions in the setting of viral infection are 
affected by this point mutation.  It is possible that, as the interaction of M2 is 
thought to be non-covalent (i.e. the M2 CT containing a SIM and not a 
SUMOylation site), interaction is through another viral protein which is 
SUMOylated, for example M1. 
4.02 SUMO interaction in the context of viral infection 
In order to understand how these mutations affect the viral lifecycle it was necessary 
to produce mutant virus using reverse genetics.  When mutant viruses F91A, V92S 
and I94M were produced, the PLA displayed interesting results different to that of 
transiently expressed M2 constructs.  F91A shared a foci/cell ratio of roughly equal 
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to that of wild type virus, V92S having around one and a half times the ratio, with 
I94M showing almost five times the number of foci per cell than wild type.  This is 
in stark contrast to the bioinformatics predictions, and the western blots of co-
immunoprecipitations with these transiently expressed mutants.  What this does 
intriguingly suggest, however, is that whilst the existence of a SIM in the M2 CT 
can be demonstrated, SUMO interactions with the M2 CT proceed very differently 
in the context of a whole virus infection.  One possibility to explain these 
phenomena is, as previously discussed with F91A, that M2 and M2 CT mutants are 
interacting with SUMO through a SUMOylated viral or cellular protein whose 
localisation and interactions with M2 are altered during virus infection.  M2 is well 
publicised to interact with M1 (McCown and Pekosz, 2006; Benjamin J Chen et al., 
2008), and M1 is known to be covalently SUMOylated at K242 and this 
modification is important for viral budding (Wu, Jeng and Lai, 2011a).  This may 
point to a necessity of M1 being present with M2 in the context of viral infection in 
order for an efficient and relevant M2-SUMO interaction to occur.  In addition, the 
PLA is unable to distinguish between direct protein binding and close protein 
association in the form of a protein complex, thus increased M2 SUMO interactions 
seen by PLA in the SIM mutants V92S and I94M may not directly represent the 
retention of SUMO binding but M2’s association in a tight protein complex with 
SUMOylated proteins. 
M2 interacts and co-immunoprecipitates with SUMO in transient plasmid-based 
expression, and this is also the case with the with M2 CT mutant F91A (ΔLIR) as 
predicted bioinformatically and seen in the Western blot (Figure 10, page 51) and 
in PLA (Figure 11, page 53).  However, when viruses containing CT mutations of 
M2 are generated and used to study the M2 SUMO interaction (Figure 12, page 53), 
an insignificant change in SUMO interaction is seen with the mutants V92S and 
F91A as compared to the wild type, with a dramatic increase in SUMO interaction 
with the I94M mutant (ΔSIM ΔLIR).  What has not been investigated is the 
potential for the CT mutations to cause a conformational change in the M2 protein 
that may alter association with viral and cellular proteins, affecting the PLA results.  
One further possibility is that the CT mutations, specifically I94M in the context of 
viral infection, causes a conformational change in the whole M2 protein, exposing 
a different site to potential SUMO interaction or SUMOylation.  Table 1 indicates 
other residues in the full length M2 which may be either SUMO interacting regions, 
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or lysine residues capable of covalent SUMOylation.  However, this is less likely 
as activity of an alternate SIM motif would likely be noticeable in the plasmid-
based co-immunoprecipitation assays.  IAV infection is known to increase global 
SUMO expression by the host cell (Pal et al., 2011; Domingues et al., 2015), and 
this, together with changes in interactions with potentially SUMOylated viral 
proteins may provide the environment for a stronger SUMO positive signal as seen 
by PLA. 
4.03 Mutations in the M2 CT can have a nuanced influence on viral 
morphology 
Data specifically regarding the M2 CT mutant F91A is in agreement in reference to 
previous literature (Beale, Wise, Stuart, Benjamin J Ravenhill, et al., 2014) that the 
inferring loss of the LIR in the F91A mutant, behaves as the F91S mutant generated 
by Beale et al in 2011.  To further this, we used viruses containing not only the 
F91A mutation, but also other CT mutations shown bioinformatically and 
transiently to interact, or not interact, with SUMO and LC3. From the 
immunofluorescence microscopy in Figure 18 (page 64), we can see an indication 
of the behaviour of this mutant in regards to protein localisation and virus 
morphology.  For all mutants except the previously reported spherical F91A mutant, 
budding of filamentous virus is seen clearly seen stained with anti-Udorn antibody, 
and with M2 aggregating at the plasma membrane and at cellular junctions.  A 
considerable amount of SUMO is also present in the viral filaments and at sites of 
virus budding where the positive staining of Udorn proteins is most prominent.  
Notably, SUMO seems to co-localise weakly with M2.  A likely explanation for the 
prevalence of SUMO at the sites of budding is not the M2-SUMO interaction but 
the SUMOylation of M1 (Wu, Jeng and Lai, 2011b), which being the most abundant 
viral protein, will incorporate a significant amount of SUMO protein in to budding 
virions.  The nucleoprotein, NP, is also known to be SUMOylated (Han et al., 
2014), and as the anti-Udorn antibody used in Figure 18 (page 64) will detect both 
M1 and NP, it is not possible to discern which viral protein is carrying SUMO in to 
the budding virion.  This may also explain the difference in resulting SUMO 
interactions in live virus infections versus transiently expressed M2 and M2 CT 
mutants, through the aforementioned possibility of an M1-M2 interaction mediated 
by SUMO, and the global SUMO expression increase upon IAV infection.  
However, in the F91A mutant, this is not the case – distinct M2-SUMO puncta are 
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clearly visible perinuclearly.  This behaviour of SUMO is not visible in the other 
mutants or the wild type, and requires speculation on two fronts; firstly, the 
localisation of F91A being perinuclear and not at the plasma membrane, and 
secondly the nature of the seemingly significant interaction between F91A and 
SUMO.  F91A is thought to lose the interaction with LC3 and prevent LC3 
recruitment to the plasma membrane; however, here we see F91A directly affecting 
M2 localisation, suggesting that M2-LC3 interactions may also affect M2 
trafficking and viral assembly.  In regards to the F91A SUMO interaction, it is 
possible that the altered M2 localisation changes M1 association with M1 or NP 
and thus the visual colocalisation between M2 and SUMO may be more obvious.   
4.04 Speculation on a role for the highly conserved residue H90 
To further understand what may be influencing the M2 SUMO interaction, a further 
residue of note in the M2 CT was identified – H90.  As seen in Figure 9 (page 49), 
H90 along with F91 is considerably well conserved, and such a synergistic 
reasoning behind this can be proposed, bringing together SUMO, LC3 and the 
interplay between the three – histidine protonation.  Histidine has the ability to be 
protonated at low pHs (Mitchell and King, 2011), such as those found in the Golgi 
apparatus (Schapiro and Grinstein, 2000), and moreover, the protonation of 
histidine in the context of viral infection has been speculated as a determinant for 
fusion of IAV in the acidic endosome, albeit through histidine residues in HA 
(Mueller et al., 2008).  That being said, the distinction between a role for H90 
protonation must be made between early and late infection.  The barrier to the idea 
that H90 may be protonated in late infection, i.e during M2 trafficking post 
translation, is that M2 retains its ion channel ability during Golgi transition.  M2 is 
able to equilibrate the pH over the Golgi with the cytoplasm, thereby neutralising 
intra-Golgi pH (Sakaguchi, Leser and Lamb, 1996).  The raising of trans-Golgi pH 
slows down the trafficking of viral and cellular proteins through the Golgi (Henkel 
et al., 2000)(Alconada, Bauer and Hoflack, 1996; Disbrow, Hanover and Schlegel, 
2005; De Jong et al., 2006), and is important for viral replication by preventing 
premature low pH triggering of HA (Skehel et al., 1982; Robert W. DomsS, Ari 
Heleniuss, 1984).  We tested the potential role for the protonation of H90 during 
virus assembly, and how this may affect M2-SUMO interactions, by using 
ammonium chloride to neutralise endosomal and Golgi pH.  In both the presence 
and absence of ammonium chloride, no difference in PLA foci ratio was seen 
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between the H90S mutant (unprotonatable) and the wild type.  This demonstrates 
that any effect of H90 on M2-SUMO interaction, at least, does not occur in the 
endosomal or budding stages of IAV infection, and that if H90 does play a role 
here, it is possible that this is during viral entry. 
4.05 M2 CT mutations may affect viral entry 
Recently, it has been reported that the ability of M2 to be ubiquitinylated plays a 
crucial role in the packaging of progeny virions, in order for efficient continuation 
of infection (Su et al., 2018).  The study notes how an M2-K78R mutation causes 
the virus to package inefficiently, with fewer vRNPs incorporated in to the newly 
forming virions, induced autophagy and apoptosis earlier than a wild type virus, 
and interacted less with M1, though the mechanism of this effect was not defined. 
The ability of M2 to bind Ubiquitin is known to be key in the uncoating and 
subsequent release and trafficking of vRNPs.  M2 and other viral components, 
through the ability to bind and carry ubiquitin in to budding virions, can exploit the 
aggresome machinery through HDAC6 to facilitate viral uncoating (Banerjee, 
Miyake, Philip Nobs, et al., 2014; Su et al., 2018).  The ubiquitin chains carried by 
M2 and incorporated in to budding viruses may play a role in triggering a HDAC6-
dependent pathway, which in turn recruits cellular machinery which is hijacked by 
IAV, facilitating viral uncoating and allowing the localisation of vRNPs to the 
nuclear membrane for import.  It is not known if other ubiquitin-like molecules, 
such as SUMO and LC3, can also trigger HDAC6 and enhance viral uncoating.  To 
study if this Ubiquitin – HDAC6 interaction may have been mediated by the ability 
of M2 CT to bind and interact with SUMO and / or LC3, immunofluorescence 
microscopy was employed to analyse viral uncoating, as seen in Figure 26 (page 
89).  The images appear to show no distinct relocalization of HDAC6 in relation to 
the mock infection, and this may point to inconsistencies in the assay itself; however 
some colocalisation of HDAC6 is seen with M1 in all samples suggesting that all 
the M2 CT mutants may retain the ability to recruit HDAC6 and uncoat, which is 
supported by the near normal level of virus replication seen with all the mutants.   
To further investigate entry and uncoating, vRNP nuclear trafficking was then 
assessed following infection for one or five hours and visualisation of vRNPs in the 
cytoplasm and nucleus, as seen in Figures 24 (page 83) and 25 (page 86).  At one 
HPI (Figure 25, page 86), vRNPs are present in the cytoplasm of all strains with a 
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minimal amount of vRNP in the nucleus.  However, this is more dramatic when 
visualised at five HPI when new vRNPs have begun synthesis.  Interestingly, V92S 
localises its vRNP to the nucleus far quicker than the other mutants (Figures 24, 
page 83 and 25, page 86), and in Figure 26 (page 89) it is also noted that the 
fluorescence signal in the M1 channel is brighter in comparison to the other 
mutants.  This evidence suggests that the initial stages of infection (from entry to 
vRNP delivery to the nucleus) happen at a faster rate in V92S than in the wild type, 
with the other mutants falling in a range – with H90S being the slowest, though at 
five HPI V92S appears to have more vRNPs retained in the nucleus while the other 
mutants appear to have begun nuclear vRNP export.  V92S causes a loss of SIM 
functionality, and a comparable interaction with LC3 compared to wild type M2, as 
predicted bioinformatically (Table 3, page 50) and confirmed via co-
immunoprecipitation (Figure 10, page 51).  Interestingly, V92S also displays a large 
amount of NP in budded virions, second only to I94M (Figure 22, page 76).  One 
possible theory may be a relationship between vRNP expression levels, affected by 
entry and uncoating timing, and M2-M1-NP-SUMO trafficking and interactions in 
the late stages of infection during viral assembly and budding.  As previously 
discussed, M1 is known to interact with M2 through its cytoplasmic tail (B. J. Chen 
et al., 2008), and M1 is known to interact with NP through its middle domain 
(Noton et al., 2007).  NP is also believed to be SUMOylated (Pal et al., 2011), along 
with M1 knowingly being SUMOylated at K242 (Wu, Jeng and Lai, 2011b).  It is 
possible that the M2 CT can freely interact with SUMOylated M1 and NP during 
IAV assembly at the site of budding, and this would be affected by M1, NP and 
vRNP expression levels and could be necessary in order to efficiently incorporate 
these proteins in to the budding virion. 
However, these results also raise the question of how mutations in the ability of the 
M2 CT to interact with SUMO are affecting viral entry and uncoating if not through 
HDAC6 interaction.  Firstly, it is unlikely that initial infection of a host cell is 
affected by a mutation in the M2 CT.  Viral attachment to a cell is mediated through 
HA binding sialic acid residues on the plasma membrane, after which an 
endocytosis event is triggered.  M2 does not play a role here, and furthermore, the 
CT is sequestered within the core of the virus and does not become exposed until 
after the viral uncoating event in the acidified endosome.  Potentially, the mutations 
within the CT of M2 may cause a conformational change within the full length of 
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M2 itself, either causing a disruption of tertiary protein structure, or the quaternary 
structure, affecting the ability of M2 to homotetramerise.  This scenario is unlikely, 
as the probable outcome of a large-scale disruption of the tertiary or quaternary 
structures of M2 would likely result in an inability of IAV to propagate, through 
disruption of the ion channel activity, or the vital interactions with other viral 
proteins, or both.  Therefore, it is likely that another process during the later stages 
of uncoating within the endosome – potentially the dissolution of the viral core and 
the release of vRNPs – is affected by these M2 CT mutations.  This is supported by 
the observation that the unprotonatable M2 CT mutant H90S appears to be 
significantly delayed in vRNP kinetics.  It is possible that H90 protonation 
facilitates the dissolution of M1-M2 association in the entering virion, facilitating 
uncoating and vRNP nuclear entry, though this was not investigated in the current 
study.  
4.06 SUMO binding and vRNP trafficking 
M2 is ubiquitinated at K78 and mutation of this site affects both autophagy and 
genome packing (Su et al., 2017).  Owing to the structural similarities of SUMO to 
ubiquitin, and the fact that this ubiquitin binding reported by Su et al. occurs in the 
cytoplasmic tail, close to the LIR/SIM motifs studied in this body of work, a role 
for SUMO and M2 during viral packaging, but not during initial infection is 
plausible.  One theory is that SUMO interaction within the M2 CT may help stablise 
M2, possibly through SIM binding of ubiquitin at K78, within the same or 
neighbouring monomers of the M2 tetramer.  Alternatively, the SUMO interaction 
may facilitate M2-M1 interaction and vRNP recruitment via binding of the M2 CT 
to SUMOylated M1.  
M2 definitively interacts with the matrix protein, M1, through residues 71 to 97, 
and mutations within this region also affect the efficient incorporation of vRNPs in 
to progeny virions (B. J. Chen et al., 2008).  M1 is known to be covalently 
SUMOylated at K242, and mutations of this residue cause a drop in viral titre, and 
an accumulation of all viral proteins, and viral RNA, within the host cell (Wu, Jeng 
and Lai, 2011b).  Having confidence that the interaction of the M2 CT with SUMO 
is not covalent in nature, a possible relationship between the accumulation of 
vRNPs in infection with M2 CT mutations could be that the M2 CT interacts with 
the covalently bound SUMO in M1 to stabilise the M2-M1-vRNP complex.  In 
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studying the localisation of vRNP staining in Figure 24 (page 83), M2 CT mutant 
V92S (lacking SUMO interaction) and mutant I94M (lacking SUMO and LC3 
binding) both cause an accumulation of vRNP within the cell nucleus, whereas the 
wild type virus does not.  Furthermore, when M1 is stained in early infection, V92S 
displays far more positive cytoplasmic staining for M1 than other mutants.  Thus, 
the M2-M1-vRNP interaction may be partly mediated though SUMO binding and 
affect vRNP trafficking and thus virus assembly and budding.  Interestingly, in the 
case of I94M which causes a loss of both LC3 binding and SIM functionality, this 
mutation appears to induce a reversion of the virus to behaviour more akin to WT 
A/Udorn/72 H3N2.  This is pertinent in the morphology of the budding virus 
(Figure 18) and the localisation of vRNPs (Figure 23, page 79), and could suggest 
that the functionality of IAV requires either both an intact LIR and SIM in the M2 
CT, or neither, but never only one. 
Results from this project propose a SUMO interaction motif (SIM) within the M2 
cytoplasmic tail (residues 92-96) which overlaps with a known LC3 interacting 
region (LIR).  Tables 2 and 3 (page 50) show that where mutations of the 
cytoplasmic tail of M2 enable an interaction with either LC3 or SUMO the 
interaction of the other is hindered or abolished.  Preliminary mass spectroscopy 
has shown that in addition to the known binding partners of M2 there are many 
other proteins which can interact with the cytoplasmic tail of M2 which may 
provide IAV with ways of circumventing autophagy, enhancing replication, 
affecting viral budding and trafficking of the virus within the cell.  The short 
cytoplasmic tail of M2 residues 82-97 seem to have a remarkable propensity to 
interact with many proteins which may be due to the lack of tertiary structure of 
these residues. 
In the data presented here, a further attempt to elucidate and understand further the 
role of M2 in the viral lifecycle, and in the ability of this small protein to influence 
cellular activity, has been undertaken.  Some further study in to the role of M2 and 
viral morphology may allow a link between the findings here of a SIM in the CT of 
M2, and the importance which M2 plays in viral genome packaging (Watanabe et 
al., 2001; McCown and Pekosz, 2005).  M2 is required for efficient NP and RNA 
packaging, and deletion of a portion of the CT causes a drop of four times in the 
ability of the virus to form competent particles, and of the particles successfully 
formed, a three log drop in infectivity.  These phenomena show that the activity of 
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M2 in viral replication is far more than ion channel activity alone.  M2 is 
characterised by ion channel activity, however we are only now, through this body 
of work and others relating to structural importance, uncovering essential roles for 
M2 beyond this.   
 
 
4.07 Further speculations on modifications of the M2 CT 
Low levels of phosphorylation of residues 82,89 and 93 has been reported by 
Holsinger et al (Holsinger, et al., 1995) to occur within the CT of M2.  Holsinger et 
al have also proposed that M2 contains the phosphorylation motif for S82 Casein 
kinase I, S89 Glycogen synthase kinase-3 and Mammary gland casein kinase for 
S93.  Phosphorylation of M2 residues 87-97 is of particular interest as mass 
spectroscopy has shown that Casein Kinase II interacts with M2 (Table 4, page 59), 
however the interaction was not observed through co-immunoprecipitation and not 
pursued further here, though it is possible there is an association that can regulate 
M2 phosphorylation to perform unknown functions.  
The data presented in this work has failed to show interaction of wild type M2 with 
SUMO in the context of viral infection by co-immunoprecipitation, that being said 
there is a repeatable and significant M2 interaction with SUMO in transfected cells 
and when assessed by PLA during virus infection.  The first explanation for these 
differing results is that the levels of M2 expression during transient plasmid-based 
expression may be considerably higher than the levels which would be observed in 
even a strong infection.  IAV virions typically contain between two and five 
tetrameric M2 assemblies, roughly ten to 20 individual M2 molecules (Zebedee and 
Lamb, 1988).  The greater abundance of M2 during transient expression, as the 
initial experiments herein were, may simply allow for a dose dependent interaction 
of M2 with SUMO through the SIM in the M2 CT.  Secondly, viral-viral protein 
interactions must be considered.  M2 has a wide and varied role during infection, 
packaging of the genome, uncoating and progeny virus release from host cells.  M2 
is known to bind to M1 through the cytoplasmic tail, and that disruptions of residues 
in the M2 CT which interfere with M1-M2 binding cause virion instability 
(Iwatsuki-Horimoto et al., 2006).  Furthermore, the M2 CT is known to bind vRNP, 
and is essential for recruitment of vRNP to the site of budding at the plasma 
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membrane, in order to facilitate viral packaging (B. J. Chen et al., 2008).  As 
opposed to covalent linkage of SUMO to the CT of M2, a weaker SUMO interaction 
is proposed here.  SUMO is known to covalently bind or non-covalently interact 
with other IAV proteins, such as M1.  M1 is known to be covalently SUMOylated 
at K242 (Wu, Jeng and Lai, 2011a), and mutation either of M1-K242 or siRNA 
knockdown of the SUMO conjugating enzyme UBC9 in target cells causes a wide 
range of viral budding and packaging discrepancies.  For example, M1-K242E 
results in a 20-fold decrease in virion production compared to wild type, whilst also 
causing a considerable accumulation of vRNP within the cell.  As an M1-vRNP 
complex is known to interact with M2 (McCown and Pekosz, 2006) a role for M2 
interacting with the SUMO bound to M1 is presented.  For example, in the context 
of viral infection the interaction of M2 with other viral proteins, namely M1 and 
vRNP, and the rate of turnover and trafficking of M2 within an infected cell, may 
simply not allow a free SUMO (i.e. not bound to M1) interaction with M1.  In 
transient expression however, the SIM in the M2 CT, the far higher abundance of 
transiently expressed M2, and the lack of other viral protein influences may allow 
the interaction of sufficient M2 in a strong enough interaction to co-
immunoprecipitate. 
As previously mentioned, SUMOylation and SUMO interacting partners play a 
crucial role within the cell.  Related closely structurally, but sharing only around 
18% sequence homology with ubiquitin (Tatham et al., 2003; van Wijk, Müller and 
Dikic, 2011), but not marking for degradation, SUMOylation is involved in 
packaging and transport of a multitude of cellular proteins.  The first identified 
SUMO binding partner was the Ran GTPase-activating protein RanGAP1, which 
is a pivotal regulatory partner of the Ras-like GTPase Ran (Lee et al., 1998).  The 
latter is a controller of export from the nucleus to the cytoplasm, and importantly 
has shown only to interact with SUMOylated RanGAP1 and not free RanGAP1 
(Mahajan et al., 1998).  This was the first reported requirement of SUMOylation 
for a native state cellular protein to perform its role.  This had implications for the 
understanding of SUMO at a deeper level, and is pertinent to this body of work in 
understanding how SUMOylation and/or SUMO interactions may influence viral 
protein folding, trafficking or localisation through either direct conjugation (in the 
case of M1) or interaction (M2).  What we speculate in regards to M2, is that SUMO 
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is acting as a bridging protein between SUMOylated proteins, and the SIM of the 
M2 CT.  
The identification of a SIM within M2 may allow SUMOylated IAV proteins (M1, 
NS1, NS2, PB1 and NP) to interact with M2 through this novel interaction.  M1 has 
been identified to interact with M2 most specifically through residues 71-76.  H90 
of M2 is a residue which is highly conserved and whose function has not been 
determined.  Protonation of H90 could occur during endosomal/lysosomal 
acidification or within an autophagosome, which could change the conformation or 
accessibility of the cytoplasmic tail and influence SIM, phosphorylation, and the 
other interaction of the cytoplasmic tail.  Chen et al., (2008) performed triple 
alanine mutations of M2 residues 89 – 91 in order to study how this would affect 
M1 incorporation in to budding virions.  This mutation showed a decreased amount 
of M1 incorporation in both virus and VLPs, and packaging of a vGFP pseudogene, 
though the mutation did not significantly affect virus growth and then effect on the 
M1-M2 interaction was not assessed.  This study demonstrated that M1 and vRNP 
binding varies along the length of M2, and residues 86-91 may exert a subtler effect 
than residues 71-76 which are most important for the interaction between M1 and 
M2.  This subtle effect may be a result of LIR and SIM. However, it is unknown as 
to whether the 88 – 91 triple alanine mutation would destroy the SIM, though it 
would interfere with LIR and with H90 protonation. 
4.08 A novel M segment splice variant, M42 
As studied in figures 27 and 29, the behaviour of the alternative M segment splice 
variant, M42, displays distinct localisation differences, as well as an effect on LC3 
colocalisation and vimentin condensation.  Retaining the same ion channel activity 
and CT as WT M2, M42 displays a different antigenic ectodomain, to which the 
14C2 antibody does not react (Wise et al., 2012).  Whilst these phenomena require 
further investigation, we can speculate on the potential for the apparent slowing of 
M42 trafficking through the Golgi causing LC3 aggregation, and vimentin 
condensation and aggresome formation.  It is possible that the formation of a clear 
vimentin cage in figure 29 (page 103) may be containing the stalled M42, and that 




4.09 Speculation on the role of the M2 CT SIM in IAV disease  
The presence of a SIM within M2, would allow IAV to interact with SUMOylated 
proteins which could contribute towards disease and pathogenicity of the virus. 
Studies have suggested that IAV may have links to acute cardiac events such as 
myocardial infarction (Warren-Gash, Smeeth and Hayward, 2009).  An interesting 
example of this could be an interaction between M2 and SR Ca2+ATPase 2a 
(SERCA2a). SERCA2a is an ATPase which is critical for Ca2+ re-uptake during 
excitation-contraction coupling, as reduced activity of SERCA2a is a hallmark of 
heart failure. SERCA2a has been shown to be SUMOylated at lysine 480 and 585 
which is essential for preserving its ATPase activity and stability (Kho et al., 2011). 
Levels of both SUMO and SERCA2a have been shown to be greatly decreased 
during heart failure. Kho et al have also shown that SUMO restitution by adeno-
associated virus-mediated gene delivery maintained the abundance of SERCA2a 
and improved cardiac function in mice.  Preliminary mass spectroscopy in this body 
of work has shown a V-type proton ATPase subunits catalytic/B/C1/E1/D/G1/H 
and transcriptional endoplasmic reticulum ATPase (Table 4, page 59) to be 
interactors of M2 in HEK-293T cells. An interaction of SUMOylated SERCA2a 
with M2 though its SIM could prevent the function of SERCA2a or M2 could 
sequester SUMO upon infection of cardiac cells, so reducing levels of SUMO and 
inducing cardiac stress during viral infection.   
SUMOylation has been shown to control the NF-KB pathway by modification of 
the inhibitory molecule IкBα (Mabb and Miyamoto, 2007), IKK subunit γ/NEMO 
(Ulrich, 2005) and the p52 precursor p100 (Vatsyayan et al., 2008). IкBα is 
SUMOylated at K21, with ubiquitin also competing for binding at this residue. 
Polyubiquitination of IкBα depends on IKK-mediated phosphorylation of residues 
32 and 36 for recognition by E3 ubiquitin ligase. In addition to independent 
SUMOylation and ubiquitination, ubiquitin forms hybrid chains on IкBα which 
increase the susceptibility of IкBα to be degraded by the 26s proteasome. IкBα 
serves as an example of the relationship between SUMO, ubiquitin and 
phosphorylation which can be applied to M2, as ubiquitin has been shown to bind 
the M2 CT by fluorescence polarisation. This interaction of ubiquitin could be 
through a UBD, or due to the sequence homology which SUMO and ubiquitin 
share. SUMO/ubiquitin chain formation within the context of IAV viral infection 
also requires investigation.  
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Finally, M2 through its SIM may be able to modulate apoptosis via an interaction 
with HSP90, which mass spectroscopy analysis conducted during this investigation 
has identified as interacting with M2 (data not shown). Hsp90 has been reported to 
be SUMOylated (Preuss et al., 2015) and as such may be able to interact with M2 
through its SIM. Hsp90 has a vast array of interacting partners which affect 
apoptosis, therefore speculation as to an M2 interaction with Hsp90 may be multi-
faceted.  Hsp90 is involved in forming a complex with IKKγ/IKKβ/CDC37 (Hinz 
et al., 2007), interaction with kinases IKKβ/Akt/Src (Sato, Fujita and Tsuruo, 2000; 
Koga et al., 2006), and inhibition of Apaf-1 and pro-apoptotic BID (Pandey, 2000). 
However a deficiency in autophagy (using ATG7 KO mouse embryonic fibroblasts) 
has been shown to impair Hsp90 induction and aberrant mTOR signalling in 
response to IAV infection (Liu et al., 2016). ATG7 is the E1-like activating enzyme 
involved in ubiquitin-like systems (including SUMOylation) required for 
cytoplasm to vacuole transport and activates ATG8 for their conjugation with 
phosphatidylethanolamine (Schulman and Harper, 2009). ATG7 is required for 
autophagic cell death induced by caspase-8 inhibition (Yu et al., 2004). Cleaved 
caspase-8 during conditions of cytoprotective autophagy co-localises with LC3-II 
and LAMP2 (Hou et al., 2010). This suggests that there may be a relationship 
between SUMO, caspase-8, Hsp90, LC3 and the cytoplasmic tail of IAV M2 that 
could play a significant role in the regulation of IAV cell death.  
4.1 USING LAIV STRAINS TO INVESTIGATE 
MORPHOLOGY 
A further investigation in to the viral factors that regulate the morphology of 
budding influenza viruses was undertaken using viruses designated as vaccine 
strains provided by MedImmune.  The LAIV used in to prepare the FluMist® nasal 
spray vaccine is prepared using a MDV backbone based on the A/Ann Arbor/6/60 
strain of IAV (Buonagurio et al., 2006), whereby only the surface antigens HA and 
NA are swapped seasonally, to invoke the desired immunogenicity relevant to 
yearly circulating influenza A virus strain.  Strains are designated according to the 
original isolated virus (e.g. Bolivia, South Dakota, Uruguay and Victoria).  
Morphology of LAIVs can therefore only be influenced by the differing HA and 
NA proteins expressed.  HA and NA have a clear effect on the appearance of viral 
filaments, producing elongated and robust filamentous budding in the Bolivia and 
South Dakota strains, with attenuated production in the Uruguay and Victoria 
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strains.  Moreover, atypical organisation of viral filaments can be seen in some of 
the vaccine strains, such as accumulations of budding IAV, Archetti bodies, and 
positively staining cell-to-cell protrusions.  The localisation of M2 (permiabilised 
samples) is distinctly nuclear in the Bolivia strain, more cytoplasmic in the South 
Dakota strain, and M2 is poorly expressed overall in the Uruguay strain.  It is known 
that the HA and NA proteins alone from certain IAV strains can drive both spherical 
VLP budding (Chen et al., 2007) and filamentous VLP budding (Chlanda, Schraidt, 
Kummer, Riches, Oberwinkler, Prinz, Kräusslich and John A. G. Briggs, 2015), 
with filamentous budding significantly enhanced through the addition of 
filamentous M segment proteins, M1 and M2.  It is important to note the ‘cold 
adapted’ nature of the LAIV strains, as this may play an important role in 
morphology.  The studies conducted herein were undertaken at 37°C, with the 
LAIV being cold adapted to 33°C, the temperature of the upper airway and site of 
replication of the LAIV (Harper et al., 2003).  Cold adaptation in vaccine strains is 
achieved through proprietary modification of the internal genes, and subsequent 
selection through passaging at lower temperatures (Maassab and Bryant, 2007).  
However, cold adaptations are also seen in the surface proteins, most notably HA 
(Lee et al., 2016), and that HA units within LAIV strains as compared to wild type 
avian strains are less thermostable (Christopher D. O’Donnell, Leatrice Vogel, 
Yumiko Matsuoka, Hong Jin, 2014).  The effect of changing temperature has been 
investigated in regards to its ability to alter its fusogenicity in certain strains 
(Schrauwen et al., 2016), though was not further investigated here. 
HA and NA have been known for some time to have significant effects on the 
morphology of budding IAV, and truncations of one or both cytoplasmic tail 
regions of these proteins cause a change in particle morphology (Jin et al., 1997).  
Although the HA from the LAIV strains used in this study are full length, there are 
many differences in the CT region of HA, speculated by Jin et al. to be responsible 
for the alterations in morphology through M1 interactions.  Further literature 
investigating the filamentous morphology of IAV postulated that M1 is the major 
driving force of filamentous budding (Elleman and Barclay, 2004), and it is well 
publicised that manipulations of the M segment between solely spherical IAVs and 
filamentous producing IAVs can also influence morphology (Noton et al., 2007; 
Bruce, Digard and Stuart, 2010).  Point mutations discussed and investigated in this 
body of work, as well as others, also describe mutations in the M2 CT as causing a 
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attenuation of filamentous virus production (McCown and Pekosz, 2006; Beale, 
Wise, Stuart, Benjamin J. Ravenhill, et al., 2014).  It is therefore a possibility that 
introducing HA to a mismatched backbone MDV can cause subtle disruptions in 
the HA CT interactions with M1 which may affect viral morphology.  However, the 
different HAs also affect autophagy induction and M2 localisation, which may 
further affect the assembly and budding of filamentous virions.  As already 
speculated, the M1 – M2 interaction may be mediated through a SIM in the M2 CT 
interacting with covalently SUMOylated M1 K242 to efficiently package and bud 
progeny virions.  Whilst mutations in the antigenic ectodomain of HA are necessary 
for efficient vaccine production, even small changes in the sequence of HAs from 
various LAIV strains may have a significant effect on the efficiency and 
morphology of IAV budding and genome packaging, though modulation of 



















4.2 IN CONCLUSION 
Understanding the influenza A virus and its nuances of infectivity, replication, 
interactions and morphology continues and will continue to be both a source of 
frustration and great intrigue in equal measure.  The reliability of annual resurgent 
disease, and its social, economic and personal impact must continue to serve as the 
main motivators in attempting to further understand the best ways to confront 
influenza virus disease.  The eventual goal being a universal influenza vaccine, 
providing very high levels of protection from all IAV strains.    
In this study, we have investigated the lifecycle of IAV, through the interactions of 
the cytoplasmic tail of the matrix protein 2.  This has been studied through both 
expanding on previous literature relating to interaction of M2 with the autophagy 
protein LC3b, and demonstration of a novel ability of M2 to interact with the small 
ubiquitin-like modifier, SUMO.  Experimentally, this has been achieved through 
the production of transiently expressible constructs of M2 CT mutants, and viruses 
produced using a reverse genetics approach which express these same M2 CT 
mutations.  Using techniques such as co-immunoprecipitation, proximity ligation 
assay, and confocal microscopy, we have presented data alluding to these M2 CT 
mutations changing the morphology of the budding virus, altering the distribution 
of vRNPs, and changing the localisation of SUMO.   
Furthermore, using LAIV strains, we have been able to analyse viral morphology 
in IAVs expressing different HA surface proteins used for producing seasonal 
influenza vaccines.  Together these results suggest that the M2 CT broadly interacts 
with ubiquitin-like molecules.  These interactions are affected by a variety of 
cellular and viral proteins and are important for proper M2 and vRNP trafficking, 
viral assembly and virion morphogenesis. 
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It is hoped that the investigations conducted for this thesis will provide the basis for 
a continuation of the study of M2 and other viral proteins in their contribution to 
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